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9:00 a.m.
1003-15 Effect of Preoperative Statins in Cardiac Valve Surgery 
Without Coronary Artery Disease
Minoru Tabata, Zain Khalpey, Lawrence H. Cohn, Ralph M. Bolman, III, James D. Rawn, 
Brigham and Women’s Hospital, Boston, MA
Background: 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have 
been shown to have pleiotropic effects in addition to their lipid lowering properties. Some 
studies have shown the beneficial effect of preoperative statins on operative outcomes 
in coronary artery bypass grafting. However, the effect of preoperative statins in cardiac 
surgical patients without coronary artery disease remains ill-defined.
Methods: We performed a retrospective review of 1389 consecutive patients undergoing 
cardiac valve surgery between January 2002 and December 2005. Patients undergoing 
concomitant coronary artery bypass surgery and those with a history of myocardial 
infarction, coronary interventions were excluded. Of this cohort, 363 patients were on a 
statin preoperatively and 1026 were not. Propensity score was constructed with patients’ 
demographic, clinical data and the year of procedure. Multivariable logistic regression 
models including the propensity score as a covariate were used to investigate whether 
preoperative statin is associated with improved operative outcomes.
Results: The statin group had older age, higher body mass index, higher frequency of 
history of smoking, hypertension, diabetes, chronic obstructive pulmonary disease and 
cerebrovascular accident, more diagnosed with aortic stenosis and fewer diagnosed 
with mitral valve disease; additionally, in this group, there was a higher frequency of 
preoperative use of beta blockers, ACE inhibitors and aspirin, and more procedures 
performed in 2005. Operative mortality was 0.8% and 2.3% in the statin and non-statin 
group, respectively. Multivariable logistic regression analysis showed that preoperative 
statin use is associated with lower mortality (odds ratio: 0.25, 95% confidential interval: 
0.07-0.91, p=0.037). It is not significantly associated with an incidence of stroke (odds 
ratio: 0.48, 95% confidential interval: 0.18-1.28, p=0.143) or perioperative myocardial 
infarction (odds ratio: 0.94, 95% confidential interval: 0.38-2.32, p=0.884) in this cohort.
Conclusion: Preoperative use of statins may improve operative outcomes in cardiac 
valve surgery without coronary artery disease.
9:00 a.m.
1003-16 Restrictive Annuloplasty and Coronary 
Revascularization in Ischemic Mitral Regurgitation: 
Long-term Results.
Nico R. Van de Veire, Jerry Braun, Jos Westenberg, Eduard Holman, Robert Klautz, 
Michel Versteegh, Ernst E. van der Wall, Robert Dion, Jeroen J. Bax, Leiden University 
Medical Center, Leiden, The Netherlands, Ghent University, Gent, Belgium
Background: Long-term follow-up data, including echocardiographic evaluation of 
reverse left ventricular (LV) remodeling, on combined coronary artery bypass grafting 
(CABG) and restrictive annuloplasty in patients with ischemic cardiomyopathy and severe 
ischemic mitral regurgitation (MR) are scarce.
Methods: Eighty-seven patients (67±10 years) with previous myocardial infarction, LV 
dysfunction and severe MR (grade 3-4+) underwent CABG and restrictive annuloplasty 
with stringent downsizing of the mitral annulus by 2 ring sizes (Physio-ring, median size 
26). All patients underwent clinical and echocardiographic evaluation before surgery: 
NYHA class, left atrial (LA) and LV dimensions, severity of MR and leaflet coaptation 
were determined. Survivors were re-evaluated at 43±16 months.
Results: Early mortality was 8% (7 pts, 4 cardiac deaths). Late mortality was 15% (13 
pts, 7 cardiac deaths). Long-term survival was 77%. As compared to survivors, patients 
who died had larger LV end-diastolic and end-systolic diameters (66±7 mm versus 60±9 
mm and 53±9 mm versus 46±11 mm, p<0.05). In survivors, NYHA class improved from 
2.9±0.8 to 1.6±0.6 (p<0.0001); LV end-diastolic and end-systolic dimensions decreased 
from 60±9 mm to 55±10 mm (p<0.0001) and from 47±11 mm to 40±12 mm (p<0.0001) 
respectively. LA dimension was reduced from 46±7mm to 43±7 mm (p<0.01). Leaflet 
coaptation improved from 3±2 mm to 7±2 mm (p<0.0001) and MR grade decreased from 
3.0±0.6 to 0.9±0.7(p<0.0001).
Conclusion: The current data confirm good clinical results of restrictive annuloplasty 
in addition to revascularization in patients with ischemic MR. Residual MR was absent 
at long-term follow-up, associated with a significant reduction in LA dimension and 
significant LV reverse remodeling.
9:00 a.m.
1003-17 Lrp5 Stem Cell Mediated Prosthetic Valve Calcification
Nalini M. Rajamannan, Frank C. Caira, Sammy Sinno, Stuart Stock, Edwin C. McGee, 
Patrick M. McCarthy, Northwestern University, Chicago, IL, Mayo Clinic, Rochester, MN
Background: Bioprosthetic valve calcification is the primary mode of valve failure. 
The cellular mechanism is not well elucidated. We tested valves from surgical valve 
replacement to establish the histologic phenotype and mechanism. 
Methods: Bioprosthetic valves removed at the time of surgical valve replacement were tested 
(N=26) as compared to controls (N=20). Immunohistochemistry was performed for alpha 
actin, osteopontin, masson trichrome, Lrp5 and mesenchymal stem cells (ckit and sca1). 
Semi-Quantitative RT-PCR was performed for C-kit and osteopontin and GAPDH in the valve. 
MicroCT was performed for evidence of calcification. Markers of angiogensis including VEGF 
and VWF were tested. Finally, inflammatory markers including CD34 and CD68 were tested.
Results: All markers of bone formation, Lrp5, mesenchymal stem cells were present in 
the bioprothetic valves as compared to control tissue (p<0.05). MicroCT confirmed the 
presence of calcification in the prosthetic RTPCR demonstrated upregulation of ckit and 
OPN (p<0.05) Alpha- actin stain was not present in the calcified bioprosthetic valves 
as compared to the controls. Angiogenesis markers were upregulated in the calcified 
prosthetic valves in areas of new vessel formation. 
Conclusions: Bioprosthetic valves demonstrated mineralization with an osteoblast-like 
phenotype. There was no evidence of native myofibroblast activation. Calcification may be 
mediated by Lrp5 activation in mesenchymal stem cells associated with angiogenesis.
Table 1
Control Valve Calcified Bioprosthetic Valves
Alpha actin 4-fold* 0.00
OPN 0.00 4-fold*
ckit 0.00 4-fold*
VEGF 0.00 3-fold*
CD34 0.00 3 -fold*
CD68 0.00 3-fold*
MicroCT 0.00 3-fold*
Lrp5 0.00 2-fold*
9:00 a.m.
1003-18 An Endocardial to Epicardial Myocardial Contraction 
Gradient is Present in Severe Compensated 
Aortic Stenosis: Does it Reverse after Aortic Valve 
Replacement?
Robert W. Biederman, June Yamrozik, Ronald Williams, Vikas K. Rathi, Diane A. Vido, 
Ketheswaram Caruppannan, Nael Osman, Saundra Grant, Geetha Rayarao, Sunil 
Mankad, James A. Magovern, Mark Doyle, Allegheny General Hospital, Pittsburgh, PA, 
Johns Hopkins, Baltimore, MD
Introduction: Experimental animal AS exhibits decreased subendocardial coronary 
flow (via microspheres) and decreased subendocardial shortening (via piezoelectric 
crystals). Such abnormalities have been shown by us and others to rapidly normalize 
following relief of AS. In late, but compensated human AS, a subendocardial to 
subepicardial strain gradient (S
endo/Sepi) via CMR is present.
Hypothesis: S
endo/Sepi myocardial strain gradient is present in severe AS but reverses 
following aortic valve replacement (AVR) in concert with LVH regression.
Methods 32 pts with late, but compensated AS underwent 3D CMR metrics (GE 1.5T, WI). 
2D intramyocardial strain via RF tagging was performed via HARP (Palo Alto, CA) of the 
endocardial and epicardial shell for 8-12 short-axis slices pre, 6mo and 12mo following AVR.
Results: 18 of 24 pts had full 2D strain available and of high quality for HARP analysis. 
Following AVR, there was marked regression of LV mass (91± 39vs 77±32g/m2, LVEDVI 
and LVESVI (79±25 vs 69±11ml and 37±29 vs 23±8ml, respectively) while EF increased 
(58±18 vs 67±10%) (p<0.001 for all). For the group composed of CAD+ and CAD- pts, 
S
endo/Sepistrain was markedly abnormal pre AVR: 0.52±0.33, was 0.56±0.51 at 6mo and 
0.59±0.49% by 12mo (all p=NS) remaining below historic controls (1.20±40%). There 
was marked improvement in absolute strains when defined by endo, midwall and epi 
segments, over time (p<0.05) and from base to mid (p<0.05) excluding the apex. In pts 
with CAD and AS, the improvements in LV metrics post AVR were further blunted (p<0.05) 
despite CABG in all. However, CAD- pts never fully approached control absolute strain or 
S
endo/Sepistrain ratios despite their marked improvements.
Conclusion: Subendocardium and subepicardium strains rapidly improve in parallel post-
AVR. However, in contrast to animal models where S
endo/Sepistrain ratios rapidly improve 
and normalize, human strain ratios do not. The rapid time course for experimental AS with 
its comparative lack of fibrosis, as compared to decades of afterload excess and fibrosis 
may be more reversible. The human strain pattern is further perturbed in those with CAD 
and its improvement is markedly blunted, favoring earlier AVR considerations.
9:00 a.m.
1003-19 Impact of Left Ventricular Geometry on Stress-
Corrected Left Ventricular Systolic Function in 
Asymptomatic Aortic Valve Stenosis. A SEAS Substudy
DANA CRAMARIUC, Åshild Rieck, Eva Staal, Erlend Eriksen, Kristian Wachtell, Anne 
Rossebø, Eva Gerdts, Institute of Medicine, University of Bergen, Bergen, Norway
Background: The impact of left ventricular (LV) geometric response to aortic stenosis 
(AS) on LV systolic function has not been studied in a large clinical study before.
Methods: Baseline echocardiography on 1720 patients with asymptomatic AS (67±10 
years, 51% hypertensive), recruited in the Simvastatin Ezetimibe in Aortic Stenosis 
(SEAS) study, was used to assess LV systolic function by fractional shortening (FS) 
and midwall shortening (MWS) corrected for circumferential end-systolic stress (scFS, 
scMWS). LV geometry was defined by LV mass/ body surface area (LV hypertrophy when 
≥ 116/104 g/m² in men/women) and relative wall thickness in combination (concentric 
geometry when ≥ 0.43). scMWS was low if < 89.2% and scFS if < 93.
Results: Patients with concentric geometry (n=328) were older, more often hypertensive, 
had higher blood pressure and FS, and lower stroke volume, MWS, scFS and scMWS 
(all p<0.05). scFS and scMWS were low in 30 and 85% of patients with concentric 
remodeling (n=166) and in 30 and 93% with concentric hypertrophy (n=162) compared 
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to 19 and 38% of those with eccentric hypertrophy (n=368) and 8 and 15% with normal 
geometry (n=1024). In logistic regression analyses, the major covariate of low scMWS 
and low scFS was concentric geometry independent of LV hypertrophy, aortic valve area/ 
body surface area, age, gender, body mass index, systolic blood pressure and history of 
hypertension (Table).
Conclusion: Concentric LV geometry is the main determinant of low scFS and scMWS 
in asymptomatic AS. 
Dependent 
variables Covariates
Odds 
ratio 95% CI P
Low scMWS Concentric geometry 30.23 20.26-45.10 <0.001
LV hypertrophy 3.30 2.51-4.33 <0.001
Aortic valve area/ body surface area 
(cm²/m²) 0.56 0.32-0.99 0.047
Male gender 1.50 1.13-1.97 0.004
Systolic blood pressure (mm Hg) 0.99 0.99-1.00 0.035
Low scFS Concentric geometry 3.58 2.58-4.96 <0.001
LV hypertrophy 2.16 1.58-2.95 <0.001
History of hypertension 0.63 0.46-0.86 0.04
Male gender 1.96 1.39-2.74 <0.001
Systolic blood pressure (mm Hg) 0.98 0.98-0.99 <0.001
9:00 a.m.
1003-20 Non-invasive Evaluation of Coronary Sinus Anatomy 
and Its Relation to the Mitral Valve Annulus: 
Implications for Percutaneous Mitral Annuloplasty
Laurens F. Tops, Nico R. van de Veire, Joanne D. Schuijf, Ernst E. van der Wall, Martin J. 
Schalij, Jeroen J. Bax, Leiden University Medical Center, Leiden, The Netherlands
Background: Recently, percutaneous mitral annuloplasty has been proposed as an alternative to 
surgical annuloplasty. In this respect, evaluation of the coronary sinus (CS) and its relation with the 
mitral valve annulus (MVA) and the coronary arteries is relevant. The feasibility of evaluating these 
issues non-invasively with Multi-slice Computed Tomography (MSCT) was determined.
Methods: In 105 patients (72 men, age 59 ± 11 years), 64-slice MSCT was performed for 
non-invasive evaluation of coronary artery disease. Three-dimensional reconstructions 
and standard orthogonal planes were used to assess CS anatomy, and its relation with 
the MVA (superior / inferior / same level) and circumflex artery (deeper / superior).
Results: In 95 patients (90%), the CS was located superior to the MVA (see Figure), in 
9 (9%) the CS was located inferior to the MVA, and in 1 patient (1%) at the same level of 
the MVA. The minimal distance between the CS and MVA was 5.1 ± 2.9 mm (range 0.5 
- 16.8 mm). In 71 patients (68%) the circumflex coronary artery coursed between the CS 
and the MVA (minimal distance 1.3 ± 1.0 mm), with a potential risk for ischemia in the 
circumflex artery region when applying percutaneous mitral annuloplasty.
Conclusions: In the majority of the patients, the CS courses superior to the MVA. In 
about 70% of the patients, the circumflex artery courses between the CS and the mitral 
annulus. Multi-slice CT may provide useful information in the selection of potential 
candidates for a percutaneous mitral annuloplasty. 
9:00 a.m.
1003-21 Epidemiology of Valvular Regurgitation in the 
Large Middle-Aged African American Cohort of the 
Atherosclerosis Risk in Communities (ARIC) Study
Richard S. Wilson, Alan Penman, Thomas Mosley, John J. King, James G. Towery, 
Kenneth Butler, Michael R. McMullan, Herman A. Taylor, Ervin R. Fox, University of 
Mississippi Medical Center, Jackson, MS
Background: Limited data are available on valvular regurgitation (VR) in African 
Americans. This study assessed the prevalence, clinical and echo correlates of mitral 
(MR), tricuspid (TR), and aortic regurgitation (AR) in a population-based sample of AA 
from the Jackson, MS site of the ARIC study.
Methods: Echos were performed in 2445 subjects. After exclusions for aortic and mitral stenosis, 
poor quality echos and missing data, 2285 remained for analysis (64% female, 36% male, aged 
50-75 yrs). Multivariable logistic regression was used to examine associations of the clinical and 
echo variables with MR, TR, and AR. For continuous variables, ORs are reported for 1 SD units.
Results: Mild or greater MR and TR were present in 13.0% and 11.6% of men and 15.6% and 
20.4% of women respectively. AR was present in 18.7% of men and 13.9% of women. MR was 
associated with age (OR = 1.14/5.8 yrs; CI, 0.98-1.32), sex (lower for men) (OR = 0.53; CI, 
0.37-0.75), lower BMI (OR = 0.66/6.1 kg/m2; CI, 0.55-0.80), systolic BP (SBP)(OR = 1.20/20.6 
mmHg; CI, 1.04-1.39), left atrial (LA) size (OR = 1.22/0.5 cm; CI, 1.05-1.43), left ventricular 
diastolic diameter (LVDD) (OR = 1.42/0.6 cm; CI, 1.19-1.68), and low LV ejection fraction (LVEF) 
(OR =3.19; CI, 1.37-7.41). TR was associated with age (OR = 1.39/5.8 yrs; CI, 1.12-1.47), sex 
(lower in men) (OR = 0.40; CI, 0.28-0.56), lower BMI (OR = 0.65/6.1 kg/m2; CI, 0.55-0.77), HDL 
(OR = 1.21/18.5 md/dL; CI, 1.06-1.39), LA size (OR = 1.19/0.5 cm; CI, 1.04-1.37), and relative 
wall thickness (0.87.0.1 cm; CI 0.77-0.98). AR was associated with age (OR = 1.35/5.8 yrs; CI, 
1.20-1.52, sex (higher in men) (OR = 1.36; CI, 1.07-1.75), lower BMI (OR = 0.86; CI, 0.74-1.00), 
SBP (OR = 1.23/20.6 mmHg; CI, 1.09-1.38), LVDD (OR = 1.35/0.6 cm; CI, 1.17-1.55), presence 
of LVH (OR = 1.65; CI, 1.28-2.14) and LVEF (OR = 2.56; CI, 1.27-5.16).
Conclusions: Detectable VR was common in this largely middle aged sample of AA. 
The prevalence of mild or greater MR and TR was similar to that seen in other (non-AA) 
cohorts. AR, however, was more prevalent. Several risk factors and echo parameters 
were identified as independent correlates of VR and were largely consistent with factors 
associated with hemodynamic load and remodeling.
9:00 a.m.
1003-22 Exercise-Induced Changes in Functional Mitral 
Regurgitation in Patients With Idiopathic Dilated 
Cardiomyopathy
Tetsuhiro Yamano, Satoshi Nakatani, Hideaki Kanzaki, Norihisa Toh, Haruhiko Abe, 
Takuya Hasegawa, Takahisa Sawada, Hiroaki Matsubara, Masafumi Kitakaze, National 
Cardiovascular Center, Osaka, Japan, Kyoto Prefectural University of Medicine, Kyoto, Japan
Background: The presence of functional mitral regurgitation (FMR) even of a mild degree is 
an independent predictor of reduced survival. However, it has not been clarified yet how mild 
FMR is so clinically important. In this study, we sought to investigate the changes of FMR during 
exercise in patients with idiopathic dilated cardiomyopathy (DCM) and its determinants. 
Methods: 28 patients with DCM underwent semi-supine exercise Doppler echocardiography 
and an effective regurgitant orifice (ERO) area of FMR was quantified using the proximal 
isovelocity surface area method at rest and during exercise. Exercise-induced changes in 
the ERO were compared with the echocardiographic measurements. 
Results: FMR did not newly appear during exercise in 8 subjects without FMR at rest. In 
17 of the remaining 20 subjects, the resting degrees of FMR were mild with an ERO less 
than 20 mm2. No one showed FMR decrease, and FMR consequently exacerbated during 
exercise in all subjects having FMR with a mean ERO from 11.2 ± 6.3 to 18.7 ± 10.4 mm2 
(p < 0.0001). The ERO changes correlated best with the changes in tenting area as an 
index of mitral deformation (r = 0.89, p < 0.0001). The independent determinants of ERO 
changes during exercise were the changes in tenting area and the resting value of ERO. 
Conclusion: FMR complicated with DCM exacerbates during exercise according to the 
changes in mitral deformation. Therefore, the clinical impact of FMR in patients with DCM 
could be more serious than can be expected by its resting degree. 
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9:00 a.m.
1003-23 Severe, Symptomatic, Mitral Regurgitation in the 
Elderly: How Many Patients are Denied Surgery and 
What are Their Characteristics?
Mariana Mirabel, Bernard Iung, David Messika-Zeitoun, Delphine Detaint, Gabriel 
Baron, Jean-Louis Vanoverschelde, Eric G. Butchart, Alec Vahanian, Bichat Hospital, 
Paris, France
Background: ACC/AHA Guidelines recommend surgery for severe, symptomatic mitral 
regurgitation (MR) (class I recommendation). The decision to operate may be more 
difficult in the elderly, however, guidelines do not give particular restrictions due to age 
itself. Little is known regarding current practices in this setting. We used the data from the 
Euro Heart Survey on valvular heart disease to identify the proportion and characteristics 
of elderly patients with severe, symptomatic, MR who were denied surgery.
Methods: Among the 5001 patients included in the Euro Heart Survey on valvular heart 
disease between April and July 2001, 877 had isolated MR. Of them, 384 were aged ≥ 70 
years, 240 of whom had severe MR, defined as MR grade ≥ 3/4, and 177 had severe MR 
and symptoms, i.e. dyspnea NYHA class II or greater.
Results: Mean age of the 177 patients was 77±5 years, 40 (23%) being aged ≥80; 28% of 
patients were in NYHA class II, 53% in class III, and 19% in class IV, 45% of patients had signs 
of heart failure at admission. Atrial fibrillation was present in 71 patients (40%). Etiology was 
degenerative in 117 (66%) patients, rheumatic in 12 (7%), ischemic in 17 (10%) endocarditis 
in 2 (1%), and other in 29 (16%). Left ventricular ejection fraction (LVEF) was 52±16%, it was 
<60% in 62% of patients and <30% in 10%. At least one comorbidity was present in 92 patients 
(52%). Mean Charlson comorbidity index was 1.6. Coronary angiography was performed in 87 
patients (49%) and showed significant coronary artery disease in 45 of them (52%).
It was decided against surgery in 114 patients (64%). In multivariate analysis, LVEF < 60% 
(p=0.0009), age ≥ 80 years (p=0.008), non-ischemic etiology (p=0.01), and a Charlson 
comorbidity index ≥ 2 (p=0.02) were associated with the decision not to operate.
Conclusion: In this contemporary survey 1) Surgery was denied in as much as two thirds of 
elderly with severe, symptomatic MR. 2) Older age and comorbidity might be valid grounds 
for deciding against surgery in certain cases. 3) Conversely, moderately decreased LVEF, 
should not lead to the denial of surgery according to current guidelines.
9:00 a.m.
1003-24 Pressure Recovery, as Assessed by Cardiovascular 
MRI, is Most Related to Aortic Impedance Rather than 
Proximal Aortic Area
Kevin Mikielski, Mark Doyle, June Yamrozik, Robert W. Biederman, Allegheny General 
Hospital, Pittsburgh, PA
Introduction: Pressure recovery in aortic stenosis (AS) has been well demonstrated to occur 
just distal to the post-stenotic vena contracta. The completeness of pressure recovery, which 
may be influenced by proximal aortic size, is inversely related to the distance between the 
stenotic orifice and vena contracta. Direct visualization of the post-stenotic vena contracta, and 
therefore the region of pressure recovery, is not possible with conventional imaging modalities, 
including echocardiography and catheterization. However, cardiovascular MRI (CMR) can 
uniquely visualize and measure post-stenotic flow characteristics and fluid dynamics, including 
the post-stenotic distance to the vena contracta.
Hypothesis: We hypothesize that the region and completeness of pressure recovery, as 
assessed by CMR, are related to proximal aortic area and aortic impedance.
Methods: Patients with severe AS who were scheduled for aortic valve replacement 
underwent preoperative CMR. CMR (GE 1.5T, Milwaukee,WI) standard LV metrics 
with phase velocity mapping, peak and mean transvalvular gradients were calculated. 
Proximal aortic area was measured throughout the cardiac cycle. An MRI measure of 
aortic impedance was defined and measured.
Results: Thirty-three pts were analyzed (mean age 68 ± 11yrs, 16F). Mean LVEF was 59 
± 17%. The mean transvalvular gradient was 61 ± 19mmHg. Through bivariate analysis, the 
post-stenotic distance to the vena contracta was not related to driving force conditions such as 
LVEF, stroke volume, transvalvular gradients and blood pressure. However, the vena contracta 
distance was most related to aortic impedance (r=0.43, p<0.05), but not to proximal aortic area 
(r=0.35, p=NS). Patients with the lowest aortic impedances had the shortest distances to the 
post-stenotic vena contracta, implying the most complete pressure recovery.
Conclusions: The region and completeness of pressure recovery, as assessed by CMR, is 
most related to aortic impedance rather than proximal aortic area. CMR allows determination 
of the post-stenotic vena contracta and aortic characteristics and may therefore become a 
noninvasive method for the assessment of pressure recovery in patients with AS.
9:00 a.m.
1003-25 Bicuspid Calcified Aortic Valves are associated 
with a splice variant of Notch1 expression in 
Human Tissues and Stenotic Bicuspid AV from 
the Hypercholesterolemic eNOS null mouse which 
Improves with Atorvastatin
Frank C. Caira, Amy L. Flores, Marva L. Rafeal, Edwin C. McGee, Patrick M. McCarthy, 
Nalini M. Rajamannan, Northwestern University, Chicago, IL
Background: Bicuspid Aortic Valve (AV) Disease occurs in 2-3% of the population. 
Recent evidence demonstrates mutations in Notch1 in patients with calcified biscuspid 
valves. We tested human calcified valves for Notch1 expression and confirmed the results 
in an animal model of bicuspid aortic valve disease to determine a mechanism.
Methods: Bicuspid AV from patients were obtained from patients (N=23) versus normal 
controls from transplantation (N=20). Western Blot, RTPCR and Immunohistochemistry 
for Notch1 expression was performed. eNOS null mouse were treated with three different 
diets: Control (N=20), Cholesterol (0.2%v/v) (N=20) and atorvastatin (N=20). The AV 
from the mice were tested for Notch1, Cbfa1, and Osteopontin. Visual Sonics 30MHz 
echocardiography confirmed the Bicuspid AV. 
Results: Notch1 in the biscuspid AV shows a decrease in normal protein expression. The 
Notch1 PCR product demonstrates a slice variant form of Notch1. We tested the control 
AV versus the cholesterol treated AV and found a similar splice variant Notch1 gene, 
not present in the control and the atorvastatin treated AV. Echocardiography confirmed 
stenosis in the bicuspid eNOS AV (See Table 1). Gene expression for Cbfa1, and 
osteopontin was increased in the cholesterol treated AV and improved with atorvastatin.
Concl: Notch1 is regulated in the human biscupid AV. Lipids regulate the Notch1 
expression and stenosis which is improved with Atorvastatin. Therefore, implicating a 
novel therapeutic target for these patients.
Table 1
*p<0.05 Cnt vs Chol
**p<0.05 chol vs Atorv Ejection Fraction (%)
Peak Velocity Across the Aortic Valve 
(m/sec)
Cont 62.11+/- 4.45 1.15+/-0.06
Chol 60.11+/- 2.66 1.52+/-0.18*
Chol+ Atorv 53.48+/-6.79 1.27+/-0.177**
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1205-268 Is There an Alternative Explanation for Post-Myocardial 
Infaction Mitral Regurgitation? Insights From Cardiac 
Magnetic Resonance
Robert W. Biederman, Ronald Williams, June Yamrozik, Ketheswaram Caruppannan, 
Vikas K. Rathi, Geetha Rayarao, Diane A. Vido, Saundra Grant, Mark Doyle, Allegheny 
General Hospital, Pittsburgh, PA
Introduction: Multiple explanations exist for the etiology of LV annular dilatation post-
MI. Current assumptions suggest an active process reflecting remodeling of adjacent 
myocardium. However, non-geometric, passive mechanisms have not been considered. 
Cardiac MRI (CMR) delayed hyperenhancement (DHE) techniques describe LV 
myocardial histopathology but may also detect non-myocardial pathology.
Hypothesis: We hypothesize that DHE may detect occult LV annular and/or mitral valve 
(MV) disease in post-MI patients and predict progression of mitral annular dilation.
Methods: One hundred sixty-four (164) pts; 111 post MI (43 F, 37 acute, 74 chronic) 
underwent CMR (1.5T GE, Milwaukee, WI) with 0.2 mmol/kg Magnevist (Berlex, Wayne, 
NJ) or 0.1 mmol/kg MultiHance (Bracco, Princeton,NJ). Retrospectively, presence/
absence of DHE pattern involving mitral annulus and/or MV was evaluated. Non-MI pts 
(53) served as controls. A subset of pts with MV enhancement (+DHE) who had follow-up 
evaluation were analyzed for annular changes.
Results: DHE was present in the mitral annulus in 49/111(44%) and in the MV in 
84/111(76%). Less commonly, DHE signal was also seen in adjacent valves: AV 
25/111(22%), TV 33/111(30%), while virtually no DHE signal was seen along the TV 
annulus 5/111(5%). Only 6/53(11%) of controls demonstrated DHE and 3/52(6%) had 
annular DHE. In the subset of 7 post-MI +DHE patients available at baseline (3±2 d) and 
up to 1 yr, there was progressive mitral annular dilation (37.9±5.1 vs. 39.0±3.0, p<0.05). 
In +DHE patients there was a trend towards progression in grade of MR: 1.6±1.4 (trace 
to trace-1+) vs. 3.6±1.9 (1+ to 1-2+), p=0.07.
Conclusion: In post MI pts, CMR DHE depicts focal annular and/or valvular enhancement 
in the majority of pts. The presence of MV enhancement was associated with progression 
of annular dilation, suggesting a specific, as yet unknown reactive process, which may 
contribute to annular dilatation and/or mitral leaflet pathology.
Noon
1205-269 Is B-Type Natriuretic Peptide Superior to Contractile 
Reserve in Predicting Outcome in Low-Flow Aortic 
Stenosis? Results From the Multicenter TOPAS Study
Jutta Bergler-Klein, Gerald Mundigler, Philippe Pibarot, Ian G. Burwash, Jean G. Dumesnil, 
Claudia Blais, Christina Fuchs, Dania Mohty, Rob S. Beanlands, Zeineb Hachicha, Florian 
Rader, Nicole Walter-Publig, Helmut Baumgartner, Med. University of Vienna, Dept. of 
Cardiology, Vienna, Austria, Quebec Heart Institute, Laval University, Sainte Foy, Canada
Background: B-type natriuretic peptide (BNP) and contractile reserve (CR) have been 
shown to be predictors of outcome in low-flow, low-gradient aortic stenosis (AS). However, 
it is unknown how they compare in their prognostic value.
Methods: BNP measurements and dobutamine stress echo (DSE) were performed in 69 
pts with low-flow AS (indexed orifice area <0.6 cm2/m2, mean gradient ≤40 mmHg, LVEF 
≤40%). Presence of CR was defined by an increase of stroke volume ≥20% at DSE. Pts 
were followed for 411±343 days.
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Results: 1-year survival was poor in pts with BNP ≥550 pg/ml but favorable in those with 
BNP <550 in the entire group (47±9% vs 97±3%; p<0.0001), as well as in the surgically 
treated group (53±13% vs 92±7%; p=0.02). Even in pts with CR, 1-year survival was 
significantly lower when BNP was ≥550 (48±12% vs 93±6%; p=0.009, Figure). More 
importantly, in the subset of pts without CR, survival was only poor when BNP was ≥550, 
but still favorable when it was <550 (50±14 vs 100%, p=0.014). After adjusting for age, 
NYHA, LVEF, CR, coronary artery disease, severity of stenosis and type of treatment, 
BNP ≥550 remained an independent predictor of outcome (p=0.0003).
Conclusion: BNP thus appears to add critical information beyond the CR assessment. 
BNP may help to identify those pts in the difficult subgroup without CR who are likely to 
benefit from valve replacement.
Noon
1205-270 Geometry of the Proximal Isovelocity Surface Area of 
Mitral Regurgitation by Three-Dimensional Color Doppler 
Echocardiography: Difference Between Functional Mitral 
Regurgitation and Mitral Valve Prolapse
Yoshiki Matsumura, Shota Fukuda, Hung Tran, Neil L. Greenberg, Deborah A. Agler, 
Nozomi Wada, Manatomo Toyono, James D. Thomas, Takahiro Shiota, Cleveland Clinic 
Foundation, Cleveland, OH
Background: Geometry of the proximal isovelocity surface area (PISA) of mitral 
regurgitation (MR) is generally assumed to be a hemisphere. However, PISA geometry of 
MR, particularly that of functional MR (FMR), remains to be clarified.
Purpose: To investigate the 3D geometry of PISA in patients (pts) with FMR as opposed 
to MR in pts with mitral valve prolapse (MVP) by using real-time 3D color Doppler 
echocardiography (RT3D).
Methods: 16 pts with FMR and 10 with MVP had RT3D. The horizontal (parallel to 
annular plane) PISA length (l) was measured in the commissure-commissure (CC) plane 
(Figure1). 3 perpendicular anteroposterior (AP) planes were generated to determine the 
maximal vertical PISA radius (r) (Figure1). The effective regurgitant orifice area (ERO) 
was calculated by using the maximal PISA radius, and compared with that by the 2D 
quantitative Doppler method (2D method).
Results: Color 3D images showed a slightly curved PISA shape along the leaflet 
coaptation line in FMR (Figure1) while the shape was rounder in MVP (Figure2). Although 
the ERO by 2D method was similar in the 2 groups, ERO by RT3D in FMR was smaller 
than that in MVP (0.20±0.12 vs. 0.46±0.24 cm2, p<0.01). The hemispherical PISA method 
with the maximal radius underestimated ERO by 2D method by 25% in FMR, while the 
agreement between the values by the 2 methods was excellent in MVP.
Conclusions: The geometry of PISA in FMR is elongated and slightly curved, distinctly 
different from the more focal pathology of MVP, leading to underestimation of ERO in FMR. 
Noon
1205-271 Tooth Extraction and Tooth Brushing Both Produce 
Bacteremia of Endocarditis-Related Pathogens
Peter B. Lockhart, Michael T. Brennan, Howell Sasser, Jenene Noll, Shirley Coleman, 
Jignya Ashar, Marie L. Kent, Philip C. Fox, Bruce J. Paster, Farah K. Bahrani-Mougeot, 
Carolinas Medical Center, Charlotte, NC
Background: The focus on prevention of infective endocarditis (IE) is on antibiotic 
prophylaxis for invasive procedures. The purpose of this study was to determine the 
incidence, nature and duration (IND) of bacteremia from tooth brushing, a routine daily 
activity, versus a single tooth extraction. 
Methods: Subjects meeting the inclusion criteria were randomized into three equal 
groups: extraction with amoxicillin, extraction with placebo, and tooth brushing. Blood 
draws for aerobic and anaerobic BACTEC cultures were drawn at six time points: at 
baseline (# 1), twice during (# 2 and 3), and at 20, 40 and 60 minutes (# 4, 5, and 
6) following these two procedures. 16S rRNA genes from all bacterial isolates were 
sequenced for species identification. 
Results: Based on our power analysis, we enrolled 290 subjects (167 males), with a mean 
age of 40 years. There was a significant difference in the incidence of positive cultures 
between the three study groups for draws 2-6 (p<0.01). The highest incidence occurred at 
draws 2 and 3 in the placebo group (79%), followed by the amoxicillin (56%) and brushing 
(28%) groups. Amoxicillin resulted in a significant decrease in bacteremia at draws 4-6 
(p<0.0001), but 2 subjects in the amoxicillin group were still bacteremic at 40 minutes. 
We identified 127 different bacterial species, the most common of which belonged to 
viridans streptococci (49%), Prevotella (9%), and Actinomyces and Fusobacterium (each 
5%) groups. Overall, amoxicillin reduced the incidence of viridans streptococci by 73%. 
However, the brushing and amoxicillin groups, and the amoxicillin and placebo groups 
were similar to each other in the incidence of some bacterial pathogens reported to 
cause IE. The placebo group had a significantly greater number of positive cultures at 
20 minutes (18%) as compared to the amoxicillin (4%) and tooth brushing (10%) groups 
(p<0.0001). Twelve percent of the placebo group and 3% of the tooth brushing group 
were still bacteremic at 60 minutes. 
Conclusions: Given the IND and daily occurrence of bacteremia, tooth brushing may 
represent a greater risk for IE than invasive dental office procedures.
Noon
1205-272 Troponin Elevation Is Highly Predictive of Outcomes in 
Patients With Infective Endocarditis
Jonathan B. Purcell, Christopher H. Cabell, James de Lemos, Lisa W. Forbess, Amit 
Khera, Mahesh J. Patel, Gail E. Peterson, UT Southwestern Medical Center, Dallas, TX
Background: Elevated troponin (↑Tn) is increasingly recognized as a marker of cardiac injury 
and poor outcome in diverse disease states. We hypothesized that patients (pts) with infective 
endocarditis (IE) and ↑Tn would have more extensive IE and worse clinical outcomes.
Methods: Patients were enrolled as part of the International Collaboration on 
Endocarditis Prospective Cohort Study; data from 83 consecutively enrolled pts from 
a single center were evaluated. TnI was drawn for clinical indications and prior to any 
surgery in 51 of the 81 pts. Outcomes evaluated were hospital mortality, abscess based 
on echo or surgery, and CNS events.
Results: Of 51 pts with Tn drawn, 33 (64.7%) had TnI > 0.1. Results stratified by TnI 
are shown in the table. There was no difference in age, gender, prosthetic valve IE, S. 
aureus IE, or prior CAD, CHF, or diabetes between the two groups. Pts with ↑TnI were 
less likely to have isolated right sided IE, had higher creatinine, and were more likely to 
have depressed LVEF (p<0.05 for each). Elevated TnI was associated with the composite 
of death, abscess, and cerebrovascular events (p<0.001). When restricted to pts with 
creatinine < 1.3 mg/dL (n=32), the association between TnI and the composite outcome 
remained significant (p<0.001).
Conclusions: Our data demonstrate a strong association of ↑TnI with the composite 
endpoint of cerebral vascular events, abscess or death in patients with IE. Further 
prospective evaluation is needed to fully define the role of troponin in IE. 
TnI positive, n (%) TnI negative, n (%) p
Mean age (yrs) 47.8 46 0.627
Male 24 (72.7) 10 (55.6) 0.214
Decreased LVEF 18 (54.5) 4 (22.2) 0.026
Mean creatinine (mg/dl) 2.3 1.1 0.042
Isolated right-sided IE 1 (3) 8 (44.4) <0.001
In-hospital death 13 (39.4) 0 0.002
Abscess 11 (33.3) 0 0.003
CNS event 15 (45.5) 1 (5.6) 0.003
Composite outcome 25 (75.8) 1 (5.6) <0.001
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1009-15 Use of Perioperative Nesiritide Improves Clinical 
Outcomes and Decreases Resource Utilization in Heart 
Failure Patients Undergoing Cardiac Surgery
Mark J. Russo, Robert E. Hobbs, Nader Moazami, Nelson Burton, Jack Copeland, 
Mehmet C. Oz, New York Presbyterian Hospital / Columbia, New York, NY, Columbia 
University, New York, NY
Bachground: To evaluate the impact of nesiritide (NES) on resource utilization, survival, 
and postoperative complications in heart failure (HF) patients undergoing cardiac surgery.
Methods: The Nesiritide Administered Peri-Anesthesia in Patients Undergoing Cardiac 
Surgery (NAPA) trial was a prospective, multicenter, randomized, double-blind trial. 
Patients (n=279) at 52 US centers undergoing CABG surgery utilizing CPB, ± MVR, 
and LVEF < = 40% were randomized to NES (0.01mcg/kg/min, no bolus) or placebo 
(PLB) plus usual care for 24-96 hrs after induction of anesthesia. GFR, adverse events, 
LOS, and 180-day mortality were pre-specified endpoints. Multivariable regression was 
302A    ABSTRACTS - Valvular Heart Disease  JACC  March 6, 2007 
Va
lv
ul
ar
 H
ea
rt
 D
is
ea
se
performed to adjust for demographics and comorbidities.
Results: Patients were randomized and treated with NES (n=141) or PLB (n=138). 
Mean age was 64±11 yrs. Hospital LOS (days) was significantly shorter (P < 0.016) in 
NES (9.1±0.7) than PLB (11.5±0.7 days). This relationship persisted after adjusting for 
risk factors in all patients and high-risk subgroups (Table). 30-day readmission rates 
were similar (P=0.387) for NES (16%) and PLB (12%). NES patients had significantly 
decreased mortality at 180 days (HR 0.44, 95% CI: 0.19-1.01, P=0.046). Postop atrial 
fibrillation (AF) and GFR decrease > 25% were also less with NES
Nesiritide vs Placebo: LOS and Postoperative Complications
Difference in regression-estimated LOS Difference (days) 95% CI P-value
All patients (n=268)* -2.2 -0.3, -4.2 0.027
CABG + other procedures (n=89) -3.6 -0.11, -7.01 0.043
Baseline GFR<60 ml/min (n=68) -3.0 1.05, -7.05 0.145
Baseline GFR > = 60 ml/min (n=200) -2.1 .24, -4.39 0.079
Postoperative complications† (n=279) NES PLB P-value‡
Atrial fibrillation 30/141 (21%) 44/138 (32%) 0.057
GFR decrease >25% from baseline 49/137 (36%) 64/134 (48%) 0.045
*N in regression analysis is the number of patients with no missing covariate values.
†30 days after start of study medication.‡Chi-square test.
Conclusions: Perioperative use of nesiritide in HF patients undergoing cardiac surgery 
significantly improved survival, reduced LOS, and decreased postop complications, 
including AF and reduced GFR.
1:30 p.m.
1009-16 Prevention of Post Operative Atrial Fibrillation with Statins 
in Persons Undergoing Isolated Aortic Valve Replacement
Somjot S. Brar, Kayvan Ellini, Aditya Ambegaonkar, Albert Yuh-Jer Shen, Prakash Mansukhani, 
Kaiser Permanente, Los Angeles, CA, UCLA School of Medicine, Los Angeles, CA
Background: Atrial fibrillation (AF) occurs commonly after cardiac surgery and has 
been associated with significant morbidity. Therapies targeted at prevention of post 
operative AF are limited.
Methods: We identified 361 consecutive patients undergoing isolated aortic valve 
replacement (AVR) at a single institution between 2000-2005 with no prior history of 
atrial fibrillation. Preoperative medication use, including statins (lovastatin, simvastatin, 
atorvastatin), was defined as >= 2 prescriptions in the 12 months prior to the surgery date. 
Statin users were divided into: non-users, low dose and intermediate-high dose users. 
Low dose included those taking <=10 mg/d of simvastatin or atorvastatin or <=20 mg/d 
of lovastatin. Multiple logistic regression was used to calculate the odds ratios and 95% 
C.I. for new onset post-operative AF. Models were validated with the Hosmer-Lemeshow 
goodness of fit test.
Results: The mean age of the cohort was 66 ± 12yr and 42% were female. The 
prevalence of preoperative statin use was 38% and post operative AF was 40%. 
Logistic Regression Analysis O.R. 95% CI p-value
Unadjusted (n=361)
Low dose vs. non-user 1.55 0.89-2.68 0.12
Intermediate-High dose vs. non-user 0.62 0.35-1.08 0.09
Adjusted* (n=361)
Low dose vs. non-user 1.10 0.57-2.11 0.78
Intermediate-High dose vs. non-user 0.47 0.25-0.91 0.02
Adjusted + left atrial size + LDL (n=261)
Low dose vs. non-user 0.96 0.46-1.98 0.90
Intermediate-High dose vs. non-user 0.32 0.15-0.68 0.003
* includes: age, gender, diabetes, heart failure, prior MI, COPD, thyroid disorder, aortic 
systolic & diastolic BP at time of cardiac catheterization, beta blocker, ACEI, ARB, 
antiarrhythmics, fasting LDL.
Conclusion: Preoperative intermediate-high dose statin use in patients undergoing 
isolated AVR was associated with a significant reduction in post operative atrial fibrillation, 
while low dose statin use was not.
1:30 p.m.
1009-17 Effect Of Valvular Replacement On Apoptotic Markers 
And Left Ventricular Diastolic Function In Patients With 
Aortic Regurgitation
Athanasios Trikas, Charalambos Antoniades, Andreas Synetos, Costantinos Toutouzas, 
Costas Tentolouris, Dimitris Tousoulis, Carmen Vasyliadou, P. Arsenos, Christodoulos 
Stefanadis, Athens University, A Cardiology Department, Athens, Greece
Background: Patients with heart failure are characterized by peripheral hypoxia due to 
low cardiac output, endothelial dysfunction and damage, as well as apoptotic process 
activation. The effects of valvular replacement on these mar-kers in patients with aortic 
regurgitation (AR) and heart failure (HF) were assessed in this study.
Methods: We studied 40 patients (mean age 56.7±5.0 years), with AR and HF (21 in 
NYHA II, 19 in NYHA III) and 30 age -and gender- matched normal volunteers (G3). 
Peripheral blood was sampled before (2±4 days, G1) and 6 months postopera-tively (G2) 
and was evaluated for plasma levels of soluble Fas / APO-1 re-ceptor (sFas, ng/ml), TNF-
alpha (TNF-a, pg/ml) and Interleukin-6 (IL-6, pg/ml) measured by ELISA method. Each 
subject underwent a complete echocardiographic study and left ventricular (LV) size and 
diastolic function were evaluated with the measurement of LV end-dia-stolic (EDD, mm), 
end-systolic (ESD, mm) diameters and the E/Vp ratio (LV peak E wave velocity to flow 
propagation velocity assessed by color m-mode Doppler) at the same times.
Results: Are shown in the table. Also, a significant positive relationship was noticed 
between E/Vp and sFas, TNF-a and IL-6 levels (r=0.70, p<0.001, r=0.67, p<0.01 and 
r=0.66, p<0.01, respectively).Conclusions: In patients with aortic regurgitation and heart 
failure, valvu-lar replacement leads to an inversion of the apoptotic process probably due 
to an improvement of cardiac size and diastolic function
(a: p<0.001 vs G1, b: p<0.01 vs G1)
sFAS TNF-a IL-6 EDD ESD E/Vp
G1 9.6±2.2 7.4±2.4 7.8±1.7 66.7± 5.8 43.2±8.5 1.7± 0.1
G2 7.1± 2.7b 5.8± 1.0b 54.7± 5.8b 36.4± 4.8a 36.4± 4.8b 1.4± 0.13b
G3 2.1± 0.4 a 4.1± 0.8a 3.8± 0.9a 39.4± 10.1a 21.4± 5.9a 0.67± 0.2a
1:30 p.m.
1009-18 Predictors Of Improvement Of Uncorrected Moderate 
Ischemic Mitral Regurgitation In Patients With Ischemic 
Cardiomyopathy Undergoing CABG Only
Martin Penicka, Hana Linkova, Otto Lang, Zbynek Straka, Richard Fojt, Martina Havlikova, 
Petr Widimsky, On behalf of the Research grant IGA 8524 and Charles University 
Research Project MSM0021620817, Cardiocenter, 3rd Medical School Charles University 
and University Hospital Kralovske Vinohrady, Prague, Czech Republic
Background: The persistence of moderate ischemic mitral regurgitation (IMR) after 
CABG is a negative determinant of survival. CABG with concomitant mitral valve repair 
is associated with significantly higher operative mortality as compared to CABG alone. 
Therefore, the aim of the present study was to identify predictors of uncorrected moderate 
IMR improvement in patients with ischemic cardiomyopathy undergoing CABG only.
Methods: The study population consisted of 121 patients with ischemic cardiomyopathy 
(age 64 ± 6, LVEF 35±10%) and moderate IMR (grade 2/4 and 2+/4) referred for CABG. 
Cardiac dyssynchrony was calculated by tissue-Doppler imaging from measurements of 
regional electromechanical coupling times in LV basal segments before and 30 days after 
CABG. Myocardial viability was assessed by MIBI/FDG SPECT before CABG.
Results: At 12 months follow-up, IMR improvement to mild or no IMR was observed in 
57 (47%) patients, no change in IMR severity in 30 (25%) patients and progression of 
IMR in the remaining 34 (28%) patients. Large extent of myocardial viability (>5 viable 
segments) and absence of pre-CABG LV dyssynchrony (<75 ms) were independently 
associated with IMR improvement (p<0.001). IMR improved in 93% of patients with 
large extent of viable myocardium but without pre-CABG dyssynchrony while only in 
34% of patients with viable myocardium and severe pre-CABG dyssynchrony (≥75 ms) 
and 21% of patients with nonviable myocardium regardless of the degree of pre-CABG 
dyssynchrony (p<0.001). Patients with persistent IMR showed significantly greater 
post-CABG dyssynchrony (120±31ms vs. 21±20ms, p<0.001) than patients with IMR 
improvement. In addition, peristence of IMR predicted, independently of other baseline 
variables, worse long-term clinical outcome (30% vs. 5% cardiovascular events, p<0.001) 
as compared to IMR improvement.
Conclusions: Presence of viable myocardium and absence of pre-CABG LV 
dyssynchrony are two major predictors of moderate IMR improvement by CABG in 
patients with ischemic cardiomyopathy. Noninvasive testing to assess myocardial viability 
and LV dyssynchrony should be considered prior CABG to guide patient selection for 
concomitant mitral valve repair.
1:30 p.m.
1009-19 Severity Of Chronic Kidney Disease As A Risk Factor For 
Operative Mortality In The California Coronary Artery 
Bypass Graft Surgery Outcomes Reporting Program
Khung-Keong Yeo, Zhongmin Li, Ezra Amsterdam, UC Davis Medical Center, Sacramento, CA
Background: Renal failure has been identified as a risk factor for operative mortality 
with coronary artery bypass graft surgery (CABG). Guidelines published by the National 
Kidney Foundation in 2002 categorize renal failure patients into 5 different classes of 
increasing severity. The relationship of this classification to risk stratification for operative 
mortality in CABG patients has not been clarified. The objective of our study is to examine 
the effect of chronic kidney disease (CKD) severity on CABG operative mortality.
Methods: Data reporting to the California Coronary Artery Bypass Graft Surgery outcomes 
reporting program (CCORP) is mandated under state law in California. Data from 121 hospitals 
on patients undergoing CABG in 2003 and 2004 were analyzed, including clinical characteristics, 
estimated glomerular filtration rate (GFR), CKD class, and observed operative mortality.
Results: There were 40,378 isolated CABG in 2003 and 2004. 8,881 (22.0%) patients had 
normal GFR (Class 1 CKD, GFR >89ml/min/1.73m2); 20,023 (49.6%) Class 2 CKD (GFR 60-
89); 9,570 (23.7%) Class 3 CKD (GFR 30-59); 843 (2.1%) CKD Class 4 (GFR 15-29); 1061 
(2.6%) Class 5 CKD (GFR <15 or on dialysis). GFR and CKD class were each significantly 
associated with operative mortality (both p<0.0001). Between successive CKD classes, 
operative mortality increased (all p<0.05), except for Classes 4 (11.5%) and 5 (10.8%). 
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Multivariate analysis showed GFR and CKD class to be significant risk factors for operative 
mortality (both p<0.0001). Compared to patients with normal renal function and CKD Class 
1, Classes 3 (OR 1.3, p=0.0167), 4 (OR 2.8, p<0.0001) and 5 (OR 4.6, p<0.0001) had 
significantly higher operative mortality. In the multivariate risk model, Classes 4 and 5 CKD 
are significant predictors of operative mortality independent of serum creatinine.
Conclusions: CKD class is an important predictor in risk stratification for operative 
mortality in patients undergoing CABG.
1:30 p.m.
1009-21 Noninvasive Left Ventricular Stroke Work Index in 
Severe Mitral Regurgitation as a Parameter of True Left 
Ventricular Performance
Jin-Oh Choi, Sang-Chol Lee, Myung Joon Park, Jun Hyung Kim, Young Bin Song, Soo 
Jin Cho, Ji Hyun Yang, Seung Woo Park, Sang Hoon Lee, Cardiac and Vascular Center, 
Department of Medicine, Samsung Medical Center, Seoul, South Korea
Background: Left ventricular (LV) stroke work index (LVSWI), an invasively obtained 
parameter, may provide more relevant information on cardiac performance in severe 
mitral regurgitation (MR) compared to ejection fraction. We sought to measure LVSWI in 
severe MR noninvasively and validate its clinical usefulness.
Methods: A prospective evaluation was performed in 29 patients with severe MR. 
Cardiac catheterization and echocardiography was done in all subjects. LVSWI was 
calculated by the following formula: (LVSWI = 0.0136 × (mean aortic pressure − LV end-
diastolic pressure(LVEDP)) × LV stroke volume index). Invasive LVSWI was measured 
by thermodilution method. Noninvasive LVSWI was calculated using echocardiographic 
measurements; LVEDP was estimated via the ratio of peak early diastolic mitral inflow 
velocity (E) to peak early diastolic mitral annular velocity (E’). The peak oxygen consumption 
rates (VO2 max) and plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels 
were measured and compared with both invasive and noninvasive LVSWI values.
Results: The mean value of noninvasive LVSWI was 33.1 ± 9.7 g∙m/m2, which showed 
good agreement with invasive LVSWI (mean; 34.9 ± 15.1 g∙m/m2, intraclass correlation 
coefficient = 0.72, p < 0.001). Noninvasive LVSWI was well correlated with Vo2 max and 
plasma NT-proBNP level (see figures). 
Conclusions: Noninvasive LVSWI may be a reliable and clinically useful parameter for 
evaluating true cardiac performance in severe MR. 
1:30 p.m.
1009-22 Clinically Relevant Valvular Heart Disease Is Rare In 
Parkinson’S Disease Patients Treated With Pergolide
Hana Linkova, Martin Penicka, E. Ruzicka, J. Roth, O. Ulmanova, L. Novakova, Martina 
Havlikova, Cardiocenter, 3rd Medical School Charles University and University Hospital 
Kralovske Vinohrady, Prague, Czech Republic
Background: Several papers showed association between therapy with pergolide, an 
ergot-derived dopamine receptor agonist, and pericardial fibrosis and implied a causal 
relationship with significant valvular heart disease. Therefore, the aim of this study was to 
investigate the relationship between the long-term use of pergolide and the prevalence of 
restrictive valvular heart disease in a larger cohort of patients.
Methods: The study population consisted of 95 patients (age 61± 9 years, 24% female) 
with Parkinson’s disease (PD) treated with pergolide and 42 healthy controls matched for 
age and gender. All subjects underwent transthoracic echo-Doppler examination. Valve 
morphology was graded as normal, restrictive or degenerative. Mitral valve tenting area 
and tenting distance were assessed from parasternal long-axis views.
Results: Average daily dose of pergolide, cumulative dose and median duration of 
treatment were 2.93±0.72 mg, 4543±1932 mg and 51.6±23 months, respectively. Severe 
valvular heart disease or pulmonary hypertension was not observed in any subject. Two 
PD patients (2.1%) and one control (2.9%) had moderate degenerative aortic regurgitation. 
Discrete fibrous thickening of the left-sided valves was noted in 16 PD patients (16.8 %) 
as compared to none of the controls (p<0.01). Mitral valve was affected in 10 patients and 
aortic valve in 6 patients. Regurgitation was not observed on any of the affected valves. In 
addition, both mitral valve tenting area (1.44±0.47 cm2 vs. 1.35±0.44 cm2, ns) and tenting 
distance (0.73±0.23 cm vs. 0.73±0.30 cm, ns) were similar in both groups.
Conclusions: In contrast to previous report, the present study did not demonstrated 
any relationship between long-term use of pergolide and clinically relevant valvular 
disease. Nevertheless, discrete fibrous changes of left-sided valves were observed 
only in PD patients treated with pergolide.
1:30 p.m.
1009-23 Increased Local Inflammatory Activation in Stenotic 
Non-rheumatic Aortic Valves: New Implications of 
Inflammation.
Konstantinos Toutouzas, Maria Drakopoulou, Eleftherios Tsiamis, John Karabelas, 
Virginia Markou, Chrysoula Patsa, Andreas Synetos, Dimitrios Iliopoulos, Stergios 
Theodoropoulos, Magdhi Yacoub, Christodoulos Stefanadis, First Department of 
Cardiology, University of Athens, Hippokratioh hospital, Athens, Greece
Background: Histological studies demonstrated inflammatory involvement in the 
progression of aortic valve (AV) stenosis. We postulated that inflammatory activation 
within the AV may lead to heat production. We investigated whether there is thermal 
heterogeneity 1) within the AV leaflets in patients (pts) with AV stenosis compared to pts 
with AV regurgitation and 2) between the stenotic AV and the ascending aortic wall (AAW).
Methods: We included pts with moderate or severe AV stenosis scheduled for AV 
replacement. Pts with rheumatic fever in their history, intercurrent inflammatory or 
neoplastic condition were excluded. Pts with AV regurgitation were used as control group. 
Temperature measurements were performed right before the hypothermical cardioplegia. 
We measured the temperature of the AAW after excluding macroscopically atherosclerotic 
lesions. Then, the temperature of the left, right and non-coronary leaflets were measured 
using a sensitive thermistor (BetaTHERM sensor, Ireland).
Results: The study population consisted of 26 pts with AV stenosis and 7 pts with 
regurgitation. Significant thermal heterogeneity was recorded within the AV leaflets in 
pts with AV stenosis compared to pts with regurgitation (1.26±0.39 vs 0.23±0.15 °C, 
p<0.01). The difference between the maximal temperature of AV and AAW was also 
greater in stenotic valves compared to valves with insufficiency (mean difference: 
1.88±0.36 vs 0.43±0.21 °C, p<0.001). The difference between the mean temperature 
of the AV leaflets and AAW was increased in pts with AV stenosis compared to pts with 
AV regurgitation (mean difference: 1.27±1.16 vs 0.22±0.14 °C, p<0.001). In pts with AV 
stenosis temperature difference between AAW and left, right and non-coronary leaflet 
was: 1.47±1.35°C, 1.45±1.29°C, and 1.30±1.31°C, respectively.
Conclusions: Non-rheumatic AV stenosis has significant in vivo thermal heterogeneity 
compared to AV regurgitation. The results of this study demonstrate an active local inflammatory 
activation in AV stenosis. Future studies need to be performed to investigate whether anti-
inflammatory treatment may have significant prognostic and therapeutic implications.
1:30 p.m.
1009-24 Coaptation Depth predicts severity of Mitral 
Regurgitation in Non Ischemic Cardiomyopathy but not 
in Ischemic Cardiomyopathy patients.
Usman R. Siddiqui, Mehul R. Bhatt, Julio A. Chirinos, Carlos Arrieta, Alexandre C. 
Ferreira, Eduardo De Marchena, Miller School of Medicine University Of Miami, Miami, FL
Background: The mechanism of functional mitral regurgitation (FMR) in ischemic 
cardiomyopathy (ICM) and non-ischemic cardiomyopathy (NICM) appears to be different. 
We aimed to better define the factors contributing to FMR in patients with ICM and NICM, 
which may impact the therapeutic approaches to FMR in these groups.
Methods: We studied 121 patients with severely reduced left ventricular ejection fraction 
(LVEF) ≤ 30%, due to ICM (n=60) or NICM (n=61), referred from 04/2003 to 08/2006. 
Age, sex, LVEF, etiology of LV systolic dysfunction, LV internal dimension in diastole 
(LVIDd), severity of FMR and coaptation area were evaluated. Patients with less than 
moderate FMR were compared with those with moderate to severe FMR.
Results: The average LVEF was 20.4% and did not differ significantly between NICM 
(LVEF=20.4%) and ICM (LVEF=20.5%, p=NS). FMR severity was not predicted by LVIDd 
(odds ratio per 1 cm increase=1.40; 95% CI=0.85-2.32; p= 0.18) or LVEF (odds ratio per 
10% increase=0.23; 95% CI=0.001-48.2; p=0.17). In univariate analysis, coaptation area 
predicted FMR severity (odds ratio for moderate to severe FMR = 2.23; 95% CI=1.04 to 
4.83; p=0.04). Stratified analyses showed that among patients with NICM, coaptation 
area was a significant independent predictor of FMR severity. After adjustment for age 
and gender, the adjusted odds ratio for each 1 cm2 increase in coaptation area was 4.33 
(95% CI=1.22-15.39; p=0.02). In contrast, among patients with ICM, coaptation area did 
not predict FMR severity (p=0.41).
Conclusion: Coaptation area, rather than LVIDd or LVEF, correlates with severity of FMR. 
Correlates of FMR differ between ICM and NICM subgroups. Mitral valve coaptation area 
independently correlates with FMR severity only in patients with NICM. These findings 
suggest a different mechanism for FMR in patients with NICM versus ICM. We speculate 
that global LV remodeling leading to alterations in the sub-valvular apparatus is a more 
important determinant of FMR in NICM.
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9:00 a.m.
1015-15 Can Preoperative Statin Use Reduce Atrial Fibrillation 
Incidence After Cardiac Surgery?
Kirkeith Lertsburapa, Craig I. Coleman, Osman Faheem, C. Michael White, Jeffrey 
Kluger, Henry Low Heart Center, Hartford Hospital, Hartford, CT
Background: Both beta-blockers and amiodarone are considered standard-of-care 
therapies in the prevention of postoperative atrial fibrillation (POAF) following cardiac 
surgery. Recent studies have demonstrated that statins - attributable in part to their anti-
inflammatory properties - may also reduce POAF, but the utilization of beta-blockers 
and amiodarone in these studies was low. Therefore, we sought to determine whether 
preoperative statin use could reduce the incidence of POAF in a population that already 
had a high background utilization of beta-blockers and prophylactic amiodarone.
Methods: Patients undergoing CABG and/or valvular surgery from the Atrial Fibrillation 
Suppression Trials II and III (AFIST II and III) randomized, controlled trials were 
evaluated in this nested cohort study. Data in respect to patient demographics, surgical 
characteristics, medication utilization and the incidence of POAF (defined as AF lasting at 
least 5 minutes in duration documented by telemetry) were all uniformly and prospectively 
collected as part of AFIST II and III. Multivariate logistic regression was utilized to calculate 
adjusted odds ratios with 95% confidence intervals.
Results: A total of 338 patients were evaluated, of which 231 (68.3%) received a statin 
preoperatively while 107 (31.7%) did not. The study population averaged 65.7 ± 9.1 
years of age, 77.8% were male, 11.2% underwent valve surgery, 3.6% had prior AF, 
10.1% had heart failure and 84.0% and 37.9% received postoperative beta-blockade and 
prophylactic amiodarone, respectively. In total, 110 (32.5%) patients developed POAF. 
Upon multivariate logistic regression, the preoperative use of statins was associated with 
a statistically significant reduction in POAF [adjusted odds ratio: 0.57 (95%CI 0.33 to 0.9, 
p=0.035)]. The use of beta-blockers and prophylactic amiodarone were also associated 
with reductions in POAF (p<0.022 for both).
Conclusions: Even in a population with appreciable beta-blocker and amiodarone use, 
adjunctive preoperative statin use was associated with a 43% reduction in patients’ 
odds of developing POAF.
9:00 a.m.
1015-16 Optimizing Transfusion in Cardiac Surgery: Deleterious 
Effects of Platelet Transfusion
Nimesh D. Desai, Gideon Cohen, Nahum Nesher, Jeri Y. Sever, George T. Christakis, Bernard 
S. Goldman, Stephen E. Fremes, Sunnybrook Health Sciences Centre, Toronto, Canada
Background: Dual antiplatelet therapy is now standard clinical practice in the setting 
of acute myocardial ischemia. Patients with severe coronary disease requiring coronary 
bypass grafting(CABG) surgery are increasingly receiving platelet transfusions to assist 
hemostasis. The purpose of this investigation was to determine clinical outcomes in 
patients receiving platelet transfusions during or after CABG.
Methods: Between 1992 and 2005, 10084 patients underwent isolated CABG and were 
followed in a prospective database. 194 patients received perioperative platelet transfusions 
but no other blood products, 1445 received platelets with other blood products and 3761 
patients received blood products but no platelets. Multiple logistic regression analysis to 
assess the role of platelet transfusion in morbidity and mortality was performed.
Results: In a fully adjusted logistic regression model, platelet transfusion was a risk 
factor for 30-day operative mortality[OR 1.7, 95%CI:1.4-2.0] independent of transfusion 
of packed red cells [OR 3.4, 2.9-4.0] and other coagulation factors [OR 1.7, 1.4-2.0]. 
Patients receiving platelet transfusions were propensity-matched on 24 variables with 
patients who underwent CABG and did not receive platelet transfusions. Perioperative 
mortality was higher in the platelet group (4.1% vs 2.5%, p<0.05). The composite endpoint 
of death, MI, and low cardiac output syndrome occurred in 26% of patients receiving 
platelets and 18% of patients who did not receive platelets (p<0.001) in this propensity-
matched comparison, which adjusted for use of other blood products. Multivariate analysis 
excluding all patients receiving packed red cells or coagulation factors (i.e. patients who 
were not clinically bleeding and received prophylactic platelet transfusion) revealed that 
platelet transfusion was an independent risk factor for the composite end-point [OR 1.9, 
1.1-3.1]. All analyses were adjusted for volume of 24 hour chest-tube loss.
Conclusions: Platelet transfusion in CABG patients was associated with increased 
mortality after controlling for use of other blood products and chest tube losses.
9:00 a.m.
1015-17 Gender Differences in Complication Rates among 
Medicare Beneficiaries Undergoing Coronary Artery 
Bypass Graft Surgery
Phillip P. Brown, Aaron D. Kugelmass, Lynn G. Tarkington, Steve D. Culler, April W. 
Simon, Cardiac Data Solutions, Inc., Atlanta, GA, Emory University Rollins School of 
Public Health, Atlanta, GA
Background: Women who undergo CABG surgery are less likely to survive than men, 
however, the differences in other adverse events are poorly understood. This research 
examines gender differences in five adverse events associated with CABG surgery.
Methods: A retrospective analysis was conducted using the Medicare Provider Analysis and 
Review Files for fiscal year 2004. The study sample consists of all hospitals that performed 
> 52 CABG surgeries during a fiscal year. The final sample consisted of 123,436 Medicare 
beneficiaries (MB) who underwent CABG surgery without concomitant valve surgery. 
Separate logistic regression equations (controlling for 25 demographic characteristics and 
co-morbidities) were estimated to predict each MB’s probability of experiencing in-hospital 
death, new onset hemodialysis, post-operative stroke, infection and ARDS. Average 
predicted rates for each adverse event were calculated for men and women.
Results: Overall, 66.9% of the MB were men and approximately 40% of the MB were over 70 
years old. The table provides the average risk adjusted adverse event rate by gender, along 
with the relative risk of women versus men experiencing each event. Women were significantly 
more likely to experience each adverse event than men and the relative risk (women/men) 
ranged from a high of 1.50x for in-hospital mortality to a low of 1.15x for infection.
Conclusion: After risk adjusting, women have significantly higher complication rates than 
men associated with CABG surgery.
Average Risk Adjusted (RA) Adverse Event Rates by Gender.
Men Women Relative Risk (w/m) p-Value
Patients 82,584 40,852
RA Mortality 3.0% 4.5% 1.50x <0.001
RA New Onset Hemodialysis 0.87% 1.10% 1.26x <0.001
RA Post Operative Stroke 1.47% 1.76% 1.19x <0.001
RA Infection 2.53% 2.91% 1.15x <0.001
RA Post Operative ARDS 5.68% 6.83% 1.20x <0.001
9:00 a.m.
1015-18 Safety of Perioperative Use of Selective and Non-
selective Cyclo-oxygenase-2 Inhibitors: a Systematic 
Analysis on 6829 Patients Undergoing Cardiac and 
Non-cardiac Surgery
Antonio Abbate, Kyong Chong, Evan Ownby, George W. Vetrovec, Giuseppe Biondi-
Zoccai, Virginia Commonwealth University, Richmond, VA
Background. Long-term use of rofecoxib leads to higher rates of major adverse 
cardiovascular and cerebral events (MACCE). Recently an increase in MACCE has been 
attributed to parecoxib, another selective COX-2 inhibitor, in patients undergoing coronary 
artery bypass graft (CABG). These data raise the question of safety of selective COX-2 
inhibitors in short- and long-term in patients undergoing surgery. Aim of this study was 
to systematically review the literature assessing the risk of selective and non-selective 
COX-2 inhibitors use in patients undergoing CABG or non-CABG surgery.
Methods. PubMed, CENTRAL, and mRCT were searched for eligible studies. We 
then performed 3 separate meta-analyses, the first (A) included all randomized studies 
comparing parecoxib with placebo in patients undergoing CABG, the second (B) 
compared parecoxib with placebo in non-CABG surgery, the third (C) included studies 
comparing of non-selective COX-2 inhibitors in CABG patients. Occurrence of MACCE 
(a composite endpoint of death, non-fatal myocardial infarction and non-fatal stroke) was 
considered the primary outcome of the analysis. Random-effect odds ratios (OR) (95% 
confidence intervals [CI]) for MACCE were computed.
Results. Data on 6829 patients were retrieved in the 3 meta-analysis. In meta-analysis 
A, 3 studies randomized patients to parecoxib (887 patients) or placebo (730 patients). 
Pooled data showed a significant increase in the MACCE rate associated with the use of 
parecoxib (OR 2.16 [1.04-4.48], P=0.040). In meta-analysis B, twenty-six studies enrolling 
2767 treated with parecoxib and 1153 patients treated with placebo were retrieved. No 
effects of parecoxib on MACCE were found. Nine studies comparing non-selective COX-
2 inhibitors with placebo were retrieved in meta-analysis C, 340 received treatment and 
241 placebo. Non-selective COX-2 inhibitors use had no impact on MACCE.
Conclusions: This systematic analysis shows an increased risk of MACCE with use of 
selective COX-2 inhibitors (parecoxib) in patients undergoing CABG but not in patients 
undergoing non-cardiac surgery. The increased risk of MACCE after CABG was not 
observed with the use of non-selective COX-2 inhibitors.
9:00 a.m.
1015-19 Pre-operative Statin Therapy Is Not Associated With 
Decrease Incidence Of Post-operative Atrial Fibrillation 
In Patient Undergoing Coronary Artery Bypass Grafting.
Salim S. Virani, MacArthur Elayda, Vijay Nambi, James M. Wilson, Christie M. 
Ballantyne, St. Luke’s Episcopal Hospital, Baylor College of Medicine, Houston, TX
Background: There is limited data in the literature if pre-operative statin therapy is 
associated with decrease in the incidence of atrial fibrillation (Afib) in patient undergoing 
coronary artery bypass grafting (CABG).
Methods: Retrospective review analysis of patients who underwent CABG at Saint 
Luke’s Episcopal hospital, from January 1, 2004 through Dec 31, 2005 was performed. 
Patients with prior history of Afib, as well as those undergoing concomitant valve surgery, 
or aortic root replacement were excluded. Baseline risk factors as well as peri-operative, 
and post-operative data was obtained on all patients. Post-op Afib was defined as the 
occurrence of Afib during the hospitalization for CABG.
Results: A total of 1543 patients were identified. Ninety seven patients were excluded 
because of the presence of chronic Afib, whereas 51 patients were excluded because 
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of concomitant CABG and valve surgery. Twenty six percent of the patients had atrial 
fibrillation (n = 365) post CABG. Multivariate logistic regression analysis showed that age 
> 65 [p=<0.001], obesity (defined as BMI > 30) [p= 0.04] and New York Heart association 
class III/ IV before CABG [p= 0.01] were all independent predictors of post-operative atrial 
fibrillation. After adjusting for above mentioned risk factors, pre-operative statin therapy 
was not associated with a decrease in the incidence of post-op Afib [RR= 1.07, 95% CI = 
0.83-1.37]. In the subset of patients with ejection fraction <35% (n = 155), pre-operative 
statin therapy was not associated with decrease incidence of post -op Afib [p = 0.62].
Conclusion: Pre-operative statin therapy is not associated with decrease in the incidence 
of post-op atrial fibrillation in patient undergoing CABG.
9:00 a.m.
1015-20 Diverging Response of Stress-induced Mitral 
Regurgitation to Exercice and Dobutamine.
Jean-Benoit le Polain de Waroux, Anne-Catherine Pouleur, Agnès Pasquet, David 
Vancraeynest, Anne-Marie D’hondt, Bernard L. gerber, Jean-Louis J. Vanoverschelde, 
Cliniques Universitaires Saint Luc, Bruxelles, Belgium
Background: In patients with left ventricular (LV) dysfunction, exercise-induced mitral 
regurgitation (MR) is an important determinant of exercise capacity and has been 
associated with a poor outcome. The present study was designed to test if, in patients 
with coronary disease, dobutamine stress-echocardiography (DbE) can induce similar 
worsening of MR than exercice echocardiography (ExE), and to explore possible 
relationship with ongoing ischemia.
Method: 29 patients (pts) (26 males, mean age: 64±15 years) with coronary disease and 
a LV ejection fraction < 45% underwent DbE and ExE on 2 separate days. ß-blockers 
were withdrawn 24 hours before each test. MR was quantified using the PISA method 
at rest and at each stage of both tests. Ischemia was identified as new or worsening of 
regional wall motion abnormalities (RWMA).
Results: Heart rate increased similarly during both tests (to 81 ± 11% and 82 ± 12% of 
max, p=ns). By contrast, systolic blood pressure (SBP) increased only with ExE (by 27 
± 22 mmHg) but decreased during DbE (by -9 ± 22 mmHg, p<0,001 vs. ExE). 15 pts 
developed RWMA during ExE and 14 during DbE. Agreement between ExE and DbE for 
stress-induced RWMA was 82% (Kappa: 0.65). During ExE, MR regurgitant volume (RV) 
increased 16/29 (55%), remained unchanged in 5/29 pts (17%) and decreased in 8/29 
pts (28%). By contrast, during DbE, 15/29 (52%) pts experienced a decrease in MR RV 
whereas only 5/29 pts (17%) showed an increase. On average, RV increased by 2 ± 6 mL 
during ExE and decreased by -5 ± 8 mL during DbE (p<0.005). No significant correlate 
to MR changes was found during ExE. By contrast, during DbE, MR RV decreased 
significantly less in pts with (by 0.5 ± 3.0 mL) than in those without (by -10 ± 9 mL, 
p<0.005) new RWMA .
Conclusion: Stress-induced changes in MR volume differ between ExE and DbE. During 
ExE, changes in MR volume are mostly driven by afterload whereas during DbE, there 
are mainly affected by the occurrence of ischemia.
9:00 a.m.
1015-21 Infective Endocarditis: Mortality Can Be Predicted by 
Kidney Function at Time of Admission
Kristine Buchholtz, Carsten Toftager Larsen, Christian Hassager, Niels Eske Bruun, 
Gentofte University Hospital, Copenhagen, Denmark, Rigshospitalet University Hospital, 
Copenhagen, Denmark
Background: Infective endocarditis (IE) is a serious disease with a high mortality 
even with optimal treatment and care. Previous studies on patients with coronary heart 
disease have shown that a decreased kidney function has a predictive prognostic value 
of mortality. If this is also true in patients with IE remains unknown.
Methods: Detailed and elaborated data-material was prospectively collected in 235 
consecutive patients with IE from October 1st 2002 to August 31st 2005 at 2 tertiary heart 
centres in Copenhagen. All patients were treated according to European guidelines. The 
mean follow-up time was 453 days (range 1-1237, SD 350). Estimated Endogenous 
Creatinine Clearance (EECC) was calculated at time of admission.
Results: Male gender: 70.2 %, mean age: 61.3 ± SD 15.0. Total mortality was 32.3% 
(76 patients), in-hospital 14.5%, and post discharge 17.8%. Patients were divided into 4 
groups according to their calculated EECC at the time of admission: 1) >90, 2) 60-90, 3) 
30-60 and 4) <30 ml/min. A Kaplan-Meyer survival plot was constructed and using Cox 
multivariate analysis a highly significant relationship between EECC and mortality was 
demonstrated, P< 0.001. We found a Hazard Ratio for mortality of 23.1% (CI 13.2-33.8) 
for every decrease of 10 ml/min in EECC, P<0.0001.
Conclusion: In patients with IE, EECC at time of admission has high and independent 
predictive prognostic value for mortality. 
9:00 a.m.
1015-22 Patient - Prosthesis Mismatch In Aortic Valve 
Replacement: Is Its Clinical Relevance Currently 
Overestimated?
Julia Mascherbauer, Raphael Rosenhek, Christina Fuchs, Elisabeth Pernicka, 
Florian Rader, Ursula Klaar, Christine Scholten, Maria Heger, Gerald Maurer, Helmut 
Baumgartner, Medical University of Vienna, Department of Cardiology, Vienna, Austria, 
Medical University of Vienna, Department of Medical Statistics, Vienna, Austria
Background: Patient-prosthesis mismatch (PPM) and its possible impact on survival 
and cardiac events after aortic valve replacement has recently gained great interest. 
However, studies on this issue have so far revealed controversial results.
Methods: The presence of PPM was assessed in 388 consecutive patients undergoing 
valve replacement for pure aortic stenosis and related to perioperative and postoperative 
mortality. As previously proposed, prosthetic valve effective orifice areas (EOA) were 
obtained from data currently available in the literature specifying valve type and size and 
were related to the patients BSA.
Results: Using the previously proposed cut-off of EOA ≤ 0.8 cm2/m2, PPM was present 
in 54% of patients. Patients were followed for 3.0±1.8 years (up to 8 years). Survival as 
estimated by Kaplan Meier analysis tended to be slightly worse in the group with PPM (1-, 
3- and 5-year survival 89%, 86% and 81% vs. 93%, 89% and 86%; p=0.18). However, 
patients with PPM were also older (73 vs 66 years, p<0.0001), more often female (64% 
vs 42%, p<0.0001), more symptomatic preoperatively (NYHA class 2.4 vs 2.2, p<0.006) 
as well as postoperatively (NYHA class 1.7 vs 1.5, p<0.005), and more frequently had 
hypertension (p=0.03) and diabetes (p=0.014). By multivariate analysis including PPM, 
age, sex, reduced left ventricular function, coronary artery disease, additional bypass 
grafting, hypertension and diabetes only age and reduced left ventricular function were 
independent predictors of survival but not PPM.
Conclusions: PPM defined and calculated as currently proposed is a frequent finding 
in patients with aortic valve prostheses. From the presented data, its impact on 
perioperative and mid-term survival appears to be overestimated. A recommendation of 
more complex surgical interventions such as aortic root enlargement to avoid PPM may 
therefore be questioned. Furthermore, it may be a major limitation of this concept to rely 
at least partially on Doppler estimates of EOA, which have been shown to markedly 
underestimate EOA in bileaflet prostheses.
9:00 a.m.
1015-23 Are There Gender Differences In Clinical Presentation 
And Surgical Outcome Of Aortic Stenosis?
Christina Fuchs, Raphael Rosenhek, Florian Rader, Uschi Klaar, Christine Scholten, 
Maria Heger, Gerald Maurer, Helmut Baumgartner, Medical University of Vienna, 
Department of Cardiology, Vienna, Austria
Background: Aortic stenosis (AS) has become the most frequent valve disease and 
has extensively been studied in recent years. Although gender differences have gained 
increasing attention in cardiolgy, little is known about gender differences in presentation 
and surgical outcome of AS.
Methods: In 439 consecutive pts. referred to surgery because of symptomatic AS 
baseline clinical and echocardiographic data as well as outcome data were analyzed with 
regard to potential gender differences.
Results: Pts. were almost equally distributed between men (n=204) and women (n=235).
At presentation, female pts. were significantly older (73±10 vs. 66±11 years; p<0,0001) 
and more symptomatic (NYHA class 2.5±0.7 vs. 2.2±0.7; p<0.0001). They also had 
smaller valve areas but this difference disappeared after adjusting for body surface 
area (0.33± 0.1 vs. 0.34±0.08 cm2/m2; p=0.21). Nevertheless, mean gradients were 
significantly higher in females (66.6±19.1 versus 62.1±20.2 mmHg, p=0.017). LV size 
did not differ when adjusting for BSA but females presented with significantly less LV 
hypertrophy although they had more frequently additional hypertension (74 vs. 58%, 
p=0.0005). Only coronary artery disease was slightly more frequent in male pts. (39% 
versus 27%; p=0.01).
Despite the higher risk profile, there was a trend towards better survival in women 
(hospital mortality 6.0% vs. 8.6%; p=0.7 and long term mortality 14.4% vs. 15.6%; p= 0.2). 
Despite improvement in both groups after surgery, women remained more symptomatic 
than men (NYHA class 1.7±0.7 vs. 1.4 ±0.55 (p=0.00002).
Conclusion: Although women with AS are older and more symptomatic than men 
when referred to surgery, operative and longterm mortality are not different. However, 
women remain more symptomatic. Further research must address whether differences 
in baseline characteristics are due to differences in disease onset and progression or 
whether females get delayed medical attention for some reasons.
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1015-24 Prosthesis-Patient Mismatch is an Independent 
Predictor of Mortality after Mitral Valve Replacement
Julien Magne, Patrick Mathieu, Jean G. Dumesnil, David Tanné, François Dagenais, 
Daniel Doyle, Philippe Pibarot, Laval Hospital Research Center/Québec Heart Institute, 
Québec, PQ, Canada
Background: We recently reported that valve prosthesis-patient mismatch (PPM) is 
associated with persisting pulmonary hypertension after mitral valve replacement (MVR). 
The objective of this study was thus to evaluate the impact of PPM on mortality in patients 
undergoing MVR.
Methods: The indexed valve effective orifice area (EOA) was estimated for each type 
and size of prosthesis being implanted in 929 consecutive patients and used to define 
PPM as not clinically significant if >1.2 cm2/m2, as moderate if >0.9 cm2/m2 and ≤1.2 
cm2/m2 and as severe if ≤0.9 cm2/m2.
Results: Moderate PPM was present in 69% of patients and severe PPM in 9%. For 
patients with severe PPM, 6-year survival (74±5%) and 12-year survival (63±7%) were 
significantly less than for patients with moderate PPM (84±1% and 76±2%; p=0.027) or 
non-significant PPM (90±2% and 82±4%; p=0.002). Moreover, in a subset of 655 patients 
with isolated MVR, patients with severe PPM had significantly lower 6-year survival 
(78±7%) and 12-year survival (71±9%) than patients with non-significant PPM (92±2% 
and 85±4%; p=0.019). On multivariate analysis, severe PPM was associated with higher 
mortality (hazard ratio: 3.2 [95% confidence interval: 1.5-6.8], p=0.003).
Conclusions: Severe PPM is an independent predictor of mortality after MVR. As 
opposed to other independent risk factors, PPM may be avoided or its severity may be 
reduced with the use of prospective strategy at the time of operation. For the patients who 
are identified to be at risk of severe PPM, every effort should thus be made to implant a 
prosthesis with a larger EOA.
9:00 a.m.
1015-25 Septal-Lateral Right Ventricular Dilatation Determines 
the Severity of Functional Tricuspid Regurgitation 
with Sinus Rhythm: A Real-Time Three-Dimensional 
Echocardiography Study
Mi-Jeong Kim, Jong-Min Song, Yong-Hyun Park, Eun-Young Lee, Yun-Jeong Kim, Duk-
Hyun Kang, Jae-Kwan Song, Asan Medical Center, Seoul, South Korea
Background: The geometric and hemodynamic determinants of functional tricuspid 
regurgitation (FTR) have yet to be clearly demonstrated.
Methods: In 15 patients with various degrees of FTR and sinus rhythm, real-time 3D 
echocardiography and 2D Doppler studies were performed. Geometries of tricuspid valve 
and right ventricle (RV) were analyzed at a mid-systolic frame using real-time 3D full-
volume images.
Results: The severity of FTR assessed by distal jet area was significantly correlated 
with tenting angles of septal (r=0.72, p<0.005) and anterior leaflets (r=0.69, p<0.005), 
septal-lateral (r=0.61, p<0.05) and antero-posterior (r=0.68, p<0.01) annulus diameters, 
tricuspid tenting volume (r=0.72, p<0.005), maximal velocity of FTR (r=0.67, p<0.01), and 
septal-lateral (r=0.87, p<0.001) and antero-posterior (r=0.83, p<0.001) RV dimensions 
measured 1 cm apart from the annulus. Septal-lateral RV dimension (p<0.001) and 
maximal velocity of FTR (p<0.05) were independent determinants of the severity of FTR 
by multiple linear regression analysis. Septal-lateral RV dimension ≥ 40 mm diagnosed 
a severe FTR (jet area ≥ 10 cm2) with a sensitivity of 100% and specificity of 100% 
(Figure).
Conclusions: RV dilatation is more essential than annulus dilatation in development of 
FTR, and septal-lateral RV dilatation is the major determinant of FTR severity in patients 
with sinus rhythm. 
9:00 a.m.
1015-26 Prediction of Postoperative Left Ventricular 
Dysfunction with Strain Rate Imaging in Patients 
with Severe Mitral Regurgitation.
Min-Seok Kim, Hyung-Kwan Kim, Hong-Gu Chun, Ho-Joon Chang, Dae-Won Sohn, 
Byung-Hee Oh, Young-Bae Park, Yun-Shik Choi, Yong-Jin Kim, Seoul National 
University Hospital, Seoul, South Korea
Background: Assessing left ventricular (LV) contractile function in patients with severe 
mitral regurgitation (MR) is a clinical problem because LV ejection phase indices such 
as ejection fraction (EF) have been limited due to the altered loading condition in these 
patients. Therefore, it is difficult to decide the timing of surgery in asymptomatic patients. 
Strain rate was reported to be useful for detecting subclinical LV dysfunction in patients 
with severe MR. The hypothesis of the present study was that radial strain rate imaging 
may be useful for assessing LV contractile function and thus predicting postoperative LV 
dysfunction in patients with severe MR.
Methods: We studied 20 patients (11 men, age: 53 ± 13 years) who had 3+ or 4+ MR 
with LV EF greater than 50%. Patients with mitral stenosis or significant other valvular 
diseases were excluded. Comprehensive 2D and Doppler echocardiography was 
performed immediately before and 6 months after surgery. Peak systolic radial strain rate 
was calculated using speckle tracking imaging in parasternal short axis view of the papillary 
muscle level. The image width and depth were adjusted to maintain the frame rate over 70 
Hz. In all patients, peak dP/dt was calculated using micromanometer-tipped catheter.
Results: Mean LVEF was 64 ± 4 % and regurgitant fraction was 61 ± 12 %. LV end-
systolic volume was 71 ± 20 ml. Peak dP/dt ranged from 1019 to 1562 mmHg/sec with 
the mean value of 1259 ± 167 mmHg/sec. Postoperative LV EF ranged from 50 to 62 
% with the mean value of 56 ± 4 %. Preoperative LVEF did not correlate with dP/dt 
nor postoperative LVEF. Although peak systolic radial strain rate did not correlate with 
preoperative LVEF (r= 0.19, p=NS), it correlated well with peak dP/dt (r=0.54, p=0.018) 
and postoperative LVEF (r=0.85, p=0.001). Interobserver and intraobserver variability of 
the measurement of strain rate were 0.10 ± 0.56/s (r= 0.64, p= 0.046) and 0.04 ± 0.24/s 
(r= 0.81, p= 0.051), respectively.
Conclusions: Peak systolic radial strain rate by speckle tracking imaging correlated well 
with peak dP/dt of LV and postoperative LVEF in patients with severe MR. It seems that 
radial strain rate is a useful parameter for evaluating contractile function in these patients.
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1021-15 Metabolic Syndrome is an Independent Predictor of 
Postoperative Renal Failure After Coronary Artery 
Bypass Surgery
Najmeddine Echahidi, Jr., Dania Mohty, Jr., Philippe Pibarot, Jr., Jean-Pierre Després, Daniel 
Doyle, Sr., Richard Baillot, Sr., Patrick Mathieu, Jr., Laval Hospital, Québec, PQ, Canada
Background: Diabetes and obesity are highly prevalent among patients undergoing 
coronary artery bypass grafting surgery (CABG). However, it remains unclear whether 
these factors have a significant impact on the occurrence of postoperative renal failure 
following CABG. We hypothesized that the metabolic abnormalities associated with the 
metabolic syndrome (MS) could negatively impact the postoperative renal function after 
CABG surgery.
Methods: We retrospectively analyzed the data of 5304 consecutive patients who 
underwent isolated CABG procedure between 2000 and 2004 at our institution. Of 
these 5304 patients, 340 (6.4%) patients with a history of renal failure and/or plasma 
creatinine≥150 µmol/l were excluded from the analysis. Of the 4964 included in the study, 
2411 (46%) had the MS according to the criteria of NCEP-ATPIII. The primary end-point 
was the development of postoperative renal failure defined as an acute elevation of 
plasma creatinine of more than 50µmol/l above the preoperative value.
Results: The incidence of renal failure following CABG surgery was 8.1% in patients 
with the MS and 4.2% in patients without the MS (p<0.0001).Univariate analysis revealed 
that age, diabetes, hypertension, peripheral vascular diseases, body mass index (BMI), 
and metabolic syndrome were all predictors of postoperative renal failure. Multivariate 
analysis confirmed that the MS was an independent predictor of renal failure RR= 1.40 
[95% CI: 1.02-1.94] (p=0.03) after adjusting for age, gender, BMI, history of diabetes, 
hypertension, and peripheral vascular diseases.
Conclusions: Using a very large cohort undergoing isolated CABG, we report that the 
MS is an independent risk factor for postoperative renal failure after cardiac surgery. 
Thus, interventions that could contribute to reduce the prevalence of the MS in patients 
with coronary artery disease or that could acutely modify the metabolic perturbations of 
the MS at the time of CABG may avoid the occurrence of renal complications that are 
predictors of mortality and morbidity and longer hospital stay in these patients.
1:30 p.m.
1021-16 Living Tissue-Engineered Heart Valves for Minimally 
Invasive Replacement Procedures
Anita Mol, Carlijn V.C Bouten, Marcel C.M Rutten, Marcel C.M Rutten, Doerthe Schmidt, 
Gregeor Zuend, Frank P.T Baaijens, Simon P. Hoerstrup, University Hospital Zuerich, 
Zuerich, Switzerland
Introduction: Tissue engineering may enable the replacement of heart valves with 
autologous, living substitutes with the capacity of growth and repair. This approach 
has demonstrated functionality in chronic animal studies and, more recently, functional 
human heart valve replacements suitable for systemic applications were presented. 
Combining the rapidly evolving technologies of minimally invasive procedures and 
tissue engineering, this study presents functional, living tissue-engineered heart valve 
substitutes for minimally invasive replacement. 
Methods and results: Trileaflet heart valves, based on rapid degrading polymer scaffolds 
attached to expandable stents, were engineered from ovine vascular derived cells. The 
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valves were grown in in-vitro bioreactor systems using diastolic loading conditions for 10 
days, subsequently seeded with endothelial cells and cultured for 4 additional days. The 
tissue-engineered valves showed excellent functionality in a valve tester mimicking the 
aortic valve environment (5 liter/min, 75 bpm) for 24 hours (Fig. 1). Testing the handling 
procedure used for minimally invasive valve replacement demonstrated intact functional 
valves without signs of structural damage. 
Conclusions: Tissue engineering and minimally invasive valve replacement technologies 
are successfully combined in this study to provide living, functional autologous valve implants. 
Large animal studies are initiated to assess process safety and long-term function.
1:30 p.m.
1021-17 Recurrent Mitral Regurgitation Late after Annuloplasty for 
Ischemic Mitral Regurgitation: An Echocardiographic Study
Maiko Shiota, A. Marc Gillinov, Shota Fukuda, Neil L. Greenberg, James D. Thomas, 
Takahiro Shiota, Cleveland Clinic, Cleveland, OH
Background: Patients who undergo ring annuloplasty for ischemic mitral regurgitation 
often have recurrent mitral regurgitation (MR). Factors that cause such recurrent MR are 
incompletely characterized. It has been suggested that late recurrent MR is caused by 
leaflet tethering and remodeling of the left ventricle (LV) that increase the sphericity of the 
LV over time. Therefore this study examined LV sphericity and its relation to late recurrent 
MR after annuloplasty.
Methods: Serial echocardiograms were reviewed in 106 patients (age 64±11 years) who 
had ring annuloplasty for ischemic MR. All had echocardiography data at least 6 months 
postoperatively, and if they had significant recurrent MR, such MR appeared only late 
after annuloplasty (>6 months). Ejection fraction (EF), left ventricular end-systolic diameter 
(LVESD), and left ventricular sphericity were analyzed in the post-operative echocardiograms 
in these 106 patients. Sphericity was calculated as the ratio of the width to the major long axis 
length (from the mitral annular plane to the apex) of the left ventricle in systole.
Results: 71 patients (67%) had satisfactory outcomes with <2+ MR (grade 0 to 4) throughout 
the follow-up period (44±31 months), while 35 patients (33%) had significant recurrent 
MR (>2+) late after annuloplasty (>6 months) during the follow-up period (45±30 months). 
Compared to those with recurrent MR, the success group had a significantly higher proportion 
of patients whose EF stayed stable or increased over the follow-up period postoperatively 
(47/70=67% versus 14/35=40%, p<0.01). In addition, the success group had a significantly 
lower sphericity of the left ventricle in systole than the failure group (0.46±0.096 versus 
0.60±0.10, p<0.01). In particular, the width of the LV was found to be significantly narrower 
in the success group compared to the failure group (3.9±1.1 cm versus 5.3±1.2 cm, p<0.01), 
while no statistical significance was found in the length of the major axis. 
Conclusion: Recurrent ischemic MR late after annuloplasty is associated with decreasing 
LVEF and increasing width and thus sphericity of the left ventricle during follow-up, 
emphasizing the ventricular mechanism of this lesion.
1:30 p.m.
1021-18 Mortality of Acute Aortic Dissection After Surgical Repair
Richard M. Chang, Nirav Mamdani, David Chen, Loma Linda University Medical Center, 
Loma Linda, CA
Background: Acute aortic dissection (AD) is a life threatening medical condition. DeBakey 
type I and II require urgent surgical repair. Debakey type III is primarily treated medically. 
The purpose of this study was to evaluate the operative (30 day) and late (5 year) mortalities 
in patients with acute AD following surgical repair according to DeBakey classification.
Methods: A consecutive series of 130 patients admitted with a transesophageal 
echocardiographic diagnosis of acute AD between 1988 and 2004 was included in the study. 
Survival analysis was performed using the Kaplan-Meier method and Log-Rank test.
Results: Of 130 patients, 91 patients had Debakey type I AD with a 30 day mortality of 
14.2% (± 3.7%). Those who survived beyond 30 days had a 5 year mortality of 17.4% 
(±4.4%). The overall 5 year mortality was 30% (± 5.2%). Of the 21 patients with type II 
AD, 30 day mortality was 9.5% (± 6.4%). Those who survived had a 5 year mortality of 
9.5% (± 9.1%). The overall 5 year mortality was 20% (± 10.2%). For type III AD, the 30 
day mortality was 22.2% (± 9.8%). The 5 year mortality for 30 day survivors was 46.5% 
(±18%). The overall 5 year mortality was 61% (± 14.9%).
Conclusions: After surgical repair, patients with Debakey type III AD had the highest 30 
day mortality rate which continued to increase throughout the 5 year follow up period. In 
patients with type I and II AD the survival rates were similar at 30 days and at 5 years 
follow up. Poor prognosis of type III patients undergoing surgical repair may need to be 
further investigated.
1:30 p.m.
1021-19 Does Pre-operative Statin Therapy Improve Outcomes 
In Patients Undergoing Cardiac Valve Surgery?
Salim S. Virani, MacArthur Elayda, Vijay Nambi, James M. Wilson, Christie M. 
Ballantyne, Baylor College of Medicine, Houston, TX, St. Luke’s Episcopal Hospital, 
Houston, TX
Background:  Pre-operative statin therapy is associated with reduced mortality after 
coronary artery bypass grafting (CABG). This benefit is independent of cholesterol 
lowering, and likely due to the anti-inflammatory (pleiotroic) properties of statins. 
Presently, there is limited data if these benefits could be extended to patients undergoing 
cardiac valve surgery. The aim of our study was to examine if pre-operative statins 
improve morbidity and mortality in patients undergoing cardiac valve surgery.
Methods: Retrospective cohort analysis of patients who underwent any surgical valvular 
repair or replacement at St. Luke’s Episcopal hospital, from Jan 1, 2001 through Dec 31, 
2005 was performed. Patients undergoing concomitant CABG, or aortic root replacement 
were excluded. Primary outcome was 30 day mortality. Secondary outcomes included 30 
day major adverse cardiac events (MACE) defined as the composite of early mortality, 
post -operative myocardial infraction (MI) or stroke. Long term follow up data was also 
obtained on all patients.
Results:  A total of 1050 patients constituted study population. Twenty eight percent 
received pre-operative statins (n = 295); 72 % did not (n= 755). Logistic regression 
analysis revealed that age > 65 (p= .002), urgent surgery (p=<0.001), history of congestive 
heart failure (p=0.005), peripheral vascular disease (p= 0.01), and need for pre-operative 
intra aortic balloon pump (p= .001) were all independent predictors of increased 30 day 
mortality. Pre-operative statin therapy was not associated with an improvement in 30 
day mortality (OR= 1.4, 95% CI 0.83-2.37), MACE (p= 0.23), or the individual outcomes 
of post-operative MI (p = 0.56), or stroke (p = 0.60). At a mean follow up of 1.2 years, 
pre-operative statin therapy was not associated with improvement in MACE or mortality. 
In the subset of patients undergoing aortic valve replacement secondary to degenerative 
valve disease (n = 256), pre-operative statin therapy was not associated with either a 
reduction in MACE or mortality.
Conclusions: Pre-operative statin therapy is not associated with a reduction in either 
morbidity or mortality in patients undergoing isolated cardiac valve surgery.
1:30 p.m.
1021-20 Aortic Regurgitation: Role of Proteoglycans in 
Myocardial Fibrosis?
Sharada L. Truter, Juliet Y. Kim, Themy F. Dumlao, Julie Heaphy, Daniel F. Catanzaro, 
Jeffrey S. Borer, Weill Medical College, New York, NY
Background: Chronic aortic regurgitation (AR) is associated with matrix remodeling. In our 
experimental rabbit model of AR we have previously reported increased glycoprotein synthesis 
and fibronectin (FN) hyperproduction. To determine any contribution of proteoglycans (PG) to 
the increased glycoprotein expression of AR, we quantified total PG synthesized by cultured 
cardiac fibroblasts (CF) and in myocardial biopsies from AR vs. NL hearts.
Method: NL vs. AR CF (n-5 pairs, triplicated) were grown in the presence of Na235SO4. 
35SO4-incorporated PG (media and lysates) from AR vs. NL CF were precipitated with 
Alcian Blue, quantified by scintillation counting and normalized to cell lysate concentration. 
Media samples were resolved by SDS-PAGE analyzed by videodensitometry and also 
digested with chondroitinase ABC to characterize secreted PG. AR vs. NL LV biopsies 
(n=5 pairs, triplicated) were homogenized in PG extraction buffer and assayed by Alcian 
Blue colorimetric assay.
Results: There was no difference (AR vs. NL CF) in total PG content in media (0.9:1, NS) 
and lysates (1.1:1, NS) following Alcian Blue precipitation. AR and NL media analysis by 
SDS-PAGE showed a major 200kDa band corresponding to a PG species sensitive to 
chondroitinase ABC digestion but no difference in expression of PG was found between 
AR and NLCF (1.0:1, NS). Myocardial biopsies from AR vs. NL LVs (5 pairs, triplicated) 
also showed no change in total PG content (1.1:1, NS).
Conclusion: PG appears to play a minor role in the pathogenesis of AR-fibrosis. Taken 
together with our previous reports, this finding suggests the predominant contributors 
to pathologic fibrosis in AR are glycoproteins, particularly FN (theoretically critical to 
myocardial force transmition). The therapeutic effect of FN modulation in AR now requires 
direct elucidation. 
1:30 p.m.
1021-21 Impact of Ischemic Mitral Regurgitation on the Outcome 
of Patients with Acute Myocardial Infarction and 
Preserved Left Ventricular Systolic Function
Doron Aronson, Robert Tzuckerman, Diab Mutlak, Jonathan Lassik, Haim Hammerman, 
Shimon Reisner, Walter Markiewicz, Yoram Agmon, Rambam Medical Center, Haifa, Israel
Background: Ischemic mitral regurgitation (IMR) has been associated with poor outcome 
after myocardial infarction (MI). However, most studies have been done in patients (pts) 
with reduced left ventricular systolic function. Very little information exists on the outcome 
of pts with IMR and preserved left ventricular ejection fraction (LVEF).
Methods: We prospectively studied 731 pts who were admitted with acute MI. 
Echocardiography was performed within 7 ± 3 days from admission. All patients had 
LVEF ≥ 45%. IMR was classified into 3 groups: 1) none, 2) mild, 3) moderate or severe. 
The primary endpoints were first re-admission for heart failure (HF) or death. The relation 
of IMR severity to the primary endpoint was evaluated using a Cox model, adjusting for 
age, sex, diabetes, hypertension, creatinine, prior infarction, Killip class, STEMI, anterior 
MI, and reperfusion therapy.
Results: Mild IMR was present in 256 pts (36.3%) and moderate/severe IMR in 24 
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pts (3.3%). During a median follow up of 24 months (6 to 48), HF or death occurred in 
5.2%, 14.7% and 41.7% of pts with no/trivial IMR, mild IMR and moderate/severe IMR, 
respectively (P < 0.0001). Compared to patients without IMR, the adjusted hazard ratio 
for HF or death was 1.9 (95% CI 1.1-3.2; P = 0.03; Figure) in pts with mild IMR and 3.5 
(95% CI 1.6-7.8; P = 0.002; Figure) in pts with moderate/severe IMR.
Conclusions: IMR is a strong independent predictor of long-term HF and death in pts 
with preserved LVEF. Even mild IMR is associated with an increased risk.
1:30 p.m.
1021-22 Effect of Mild to Moderate Chronic Kidney Disease on 
Progression of Calcific Aortic Stenosis
Charlotte Ng, Masoor Kamalesh, Hicham El Masry, George Eckert, Stephen Sawada, 
Indiana University Medical Center, Indianapolis, IN
Background: While end stage renal disease (ESRD) is known to accelerate progression 
of calcific aortic stenosis (CAS) of native valves, effect of mild to moderate chronic kidney 
disease (CKD) is unknown. Since abnormalities in calcium and phosphate metabolism 
accompany CKD, we hypothesized that CKD adversely affects CAS disease progression.
Methods: We retrospectively analyzed 160 consecutive patients with CAS between 1/97- 
3/05, referred to our laboratory for serial echocardiograms. Two readers independently 
measured the aortic valve area (AVA) using the continuity equation. CKD was classified 
from Stage I-IV on basis of creatinine clearance (Cr. Cl.) >90, 89-60, 59-30 and 29-15 
ml/min. The effect of baseline renal function stage on CAS progression was analyzed 
using Spearman correlation coefficients and analysis of variance.
Results: 10 subjects were excluded as they were on dialysis or had Cr. Cl. < 14 ml/
min. Mean age was 69±9 years. At baseline, 58 pts had mild AS (AVA=1.93±0.40 cm2), 
68 moderate AS (AVA=1.24±0.14 cm2) and 24 severe AS (AVA=0.81±0.13 cm2). CKD 
subjects in stage 1 n =34, Stage 2 n=61, Stage 3 n=50, Stage 4 n=5.The correlation 
between baseline renal function and CAS progression was not statistically significant: 
correlation = -0.01 (p=0.86). The four baseline CKD stages did not have significantly 
different CAS progression (p=0.97): stage 1 mean -0.15, stage 2 mean -0.16, stage 3 
mean -0.15, stage 4 mean -0.13
Conclusions: Mild to moderate CKD does not accelerate progression of CAS. This may 
be due to the moderate changes in calcium and phosphorus metabolism seen in CKD 
compared to severe changes in ESRD.
1:30 p.m.
1021-23 LXR Agonist T1317 Inhibits the Aortic Valve 
Calcification in ApoE-/- Mice
Haimei Wang, Lawrence Czer, Alfredo Trento, Cedars Sinai Medical Center, Division of 
Cardiothoracic Surgery, Los Angeles, CA
Background: Calcification plays a major role in the failure of bioprosthetic and native 
heart valves. Recent evidence suggests that hypercholesteremia may be a risk factor 
in bioprosthetic valve calcification. The liver X receptor (LXR) plays a key role in the 
regulation of cholesterol and phospholipid metabolism. It has been shown that LXR 
agonist T1317 reduced atherosclerotic plaques in a mouse model of apoE deficiency 
(apoE-/-). However, the functional relevance of LXRs in valvular disease has not been 
investigated. We hypothesized that LXR agonists may reduce the atherosclerotic lesions 
in the native valve and decrease bioprosthetic valve calcification in apoE-/- mice fed a 
high cholesterol diet.
Methods: We established two groups of eight apoE-/- mice. All mice received 
subcutaneously implanted fragments of porcine valves (fixed in 0.6% glutaraldehyde). 
One group was treated with T1317 and the other with vehicle for eight weeks. Both 
groups of mice received a high cholesterol diet. Calcium and lipid levels of the explanted 
tissues were quantified. The atherosclerotic lesions in native aortic root were measured 
and cytokine levels in serum of mice from both groups were compared.
Results: The concentration of calcium [3.09 ± 1.02 mg/g dry tissue vs 4.29 ± 0.78 mg/g 
dry tissue (p < 0.05)] and lipid [0.358 ± 0.046 mg/g vs 0.44 ± 0.064 mg/g tissue (p < 0.01)] 
in explanted tissue was significantly lower in mice treated with the LXR agonist vs vehicle, 
respectively. The ratio per leaflet area of atherosclerotic lesions in native aortic valves 
was less in mice treated with T1317 at 0.16 ± 0.07 % vs vehicle 0.33 ± 0.032 % or control 
0.37± 0.007% ( p<0.002). LIX and CD30T chemokines were 5- and 2.5-fold increased 
while PF4 was 1.5-fold decreased in treated mice. Serum LDL and total cholesterol levels 
were lower in treated mice compared to control mice (p< 0.01).
Conclusions: Our data suggest that the regulation of lipid metabolism plays a very 
important role in valvular calcification. We implicate chemokines in reduction of valve 
calcification regulated by LXR. The data indicate that LXR could be an effective therapeutic 
target to reduce bioprosthetic or native valve calcification by inhibition of lipid deposition.
1:30 p.m.
1021-24 Effect of Pulmonic Stenosis on Pregnancy - A Case 
Control Study
Uri Elkayam, Afshan Hameed, Deborah A. Wing, T. Murphy Goodwin, University of 
Southern California, Los Angeles, CA
Background: Mitral and aortic stenosis in pregnancy have a significant impact on 
maternal and fetal health. The purpose of this study is to evaluate pregnancy outcomes 
in patients with pulmonic stenosis (PS)
Methods: Case-control cohort study of 17 cases complicated by PS in pregnancy from 
1995-2003. Eight pregnancies were reviewed retrospectively and nine were followed 
prospectively. Control group was matched to the study population by age, ethnicity, 
obstetrical history, and the year of delivery. Peak gradient of less than 50 mm Hg across 
pulmonary valve was categorized as mild PS, and more than 50 as severe. Maternal 
NYHA functional class at baseline and during pregnancy, fetal outcomes including birth 
weight, placental weight, gestational age at delivery, and apgar scores were compared 
between the two groups and controls.
Results: Eleven patients were in NYHA functional class I, and 6 in class II at the time of 
presentation. All patients remained stable during the course of pregnancy except one who 
deteriorated from NYHA functional class I to II. There was no significant difference in the fetal 
outcomes between cases and controls in both mild and severe PS as shown in the table.
Overall Fetal Outcomes
Peak 
Gradient 
(mm Hg)
Average 
Maternal 
Age 
(years)
Birth 
Weight 
(grams)
Placental 
Weight 
(grams)
Gestational 
Age @ 
Delivery 
(weeks)
Apgar 
score @ 
1 minute
Apgar 
score @ 5 
minutes
Mild PS <50 (33.8 
± 10.7) 22.9
3198 ± 
569 681 ± 205 39.5 ± 1.6 8.7 ± 0.5 9.2 ± 0.5
Severe 
PS
50 or 
more 
(82.3 ± 
28.4)
26.5 3192 ± 553 597 ± 150 37.5 ± 2.2 7.2 ± 3.1 7.7 ± 2.8
Control - 24.3 3360 ± 432 693 ± 421 39.3 ± 1.2 8.6 ± 0.5 8.9 ± 0.2
Conclusions: In contrast to mitral and aortic stenosis, PS regardless of its severity does 
not adversely impact maternal or fetal outcomes.
1:30 p.m.
1021-25 Is Wilkins Score a Predictor of Echocardiographic 
Restenosis in Young Population After Percutaneous 
Mitral Balloon Valvotomy?
Arturo R. Quizhpe, Sergio L. Braga, Nísia L. Gomes, Zilda Meneguello, Alexandre 
Abizaid, Fausto Feres, Galo Maldonado, Marco Pastrana, Andrea Abizaid, Amanda 
Sousa, Eduardo MR Sousa, César A. Esteves, Instituto Dante Pazzanese de 
Cardiologia, Sao Paulo, Brazil
Background: Previous studies have shown satisfactory immediate and mid-term 
outcomes after percutaneous mitral balloon valvotomy (PMV), specially in young patients 
with low Wilkins score (WS). Nevertheless, this score has not been related to restenosis 
in selected populations. The purpose of our study is to investigate the role of WS as a 
predictor of restenosis in young population at mid-term follow-up.
Methods: We included 349 consecutive patients ≤40 years old, with symptomatic mitral 
stenosis from January 2000 to March 2006. All procedures were performed using the Inoue 
technique with a 91% of success. The mean follow-up was 39±20mos. Restenosis at follow-
up was defined as a loss of >50% of the initial gain in the mitral valve area (MVA) after PMV.
Results: Mean age was 30 years old, females were 84% and mean WS was 8.7. Atrial 
fibrilation was present in 6% and 39% of the patients had discrete mitral insufficiency 
before PMV. After dividing the patients into two groups according to the WS (GI ≤8 and 
GII >8) midterm events were similar in both (death 1.7% vs 0%, p=ns; stroke 0% vs 0%; 
restenosis 16.1% vs 13.2%, p=ns; repeated BMV 5% vs 3.9%, p=ns; and mitral valve 
replacement 6.6% vs 9%, p=ns; respectively). Multivariate analysis showed that WS was 
not an independent predictor of restenosis whereas MVA and grade 2 mitral regurgitation 
post-procedure were predictors.
Conclusions: Wilkins score was not related to echocardiographic restenosis in this 
population. However, MVA and a detriment in mitral regurgitation post-PMV were predictors.
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Heart Disease
Monday, March 26, 2007, 2:00 p.m.-3:30 p.m.
Room 206-207
2:00 p.m.
816-3 Early Improvement In Left Ventricular Systolic Function 
Following Retrograde Transfemoral Aortic Valve 
Implantation
Kohei Fujimoto, Susheel Kodali, Roy Pizzarello, Shunichi Homma, Michael Collins, 
Mat Williams, Mehmet Oz, Sanford Litwin, Jeffrey Moses, Martin B. Leon, Columbia 
Presbyterian Medical Center, New York, NY
Background: Recent studies have demonstrated that transfemoral aortic valve 
replacement (TAVR) may be feasible in high-risk patients. There is limited data regarding 
the effect of TAVR on recovery of left ventricular function.
Methods: : Digital 2D echo images were obtained at baseline and 30 days post TAVR, 
and LV function was quantitatively analyzed by an independent echocardiographer 
using modified Simpson’s method. Ejection fraction (EF) at 30 days following TAVR was 
compared to baseline.
Results: A total of 21 patients (67% female, mean age - 84 years old) with severe 
symptomatic aortic stenosis (mean valve area 0.48 cm2) and mean Logistic Euroscore 
30% underwent successful TAVR with all post-procedure valve areas >1.7cm2. Mean 
EF in all patients increased from 45±14% at baseline to 52±13% at 30 days (p<0.01). 
In patients with a low EF (<50%), the improvement in LV function at 30 days was more 
prominent (35 ± 8 vs. 45 ± 12; p<0.01) compared to patients with an EF > 50% (60 ± 4 vs. 
62 ± 5; p=0.02) (table). In patients with an EF<50%, there was a higher incidence of prior 
coronary revascularization (75% vs. 33%; p=0.09).
Conclusions: Left ventricular systolic function recovers early following percutaneous 
AVR, particularly in patients with low baseline EF. Six month echocardiographic 
findings will be reported. 
2:15 p.m.
816-4 In-Hospital and 30 Day Outcomes Following Retrograde 
Trans-Femoral Aortic Valve Replacement in High-Risk 
Patients: A Report from the REVIVAL-II Trial
Susheel Kodali, Jeffrey Moses, Michael Collins, Mat Williams, Allan Stewart, Roy 
Pizzarello, Sanford Litwin, Allan Schwartz, Martin B. Leon, Columbia University Medical 
Center, New York, NY
Background: There is currently a significant population of untreated patients with severe 
aortic stenosis (AS) that would benefit for trans-femoral aortic valve replacement (TAVR). We 
report the early results using the Cribier Edwards percutaneous heart valve (PHV) in elderly 
patients at high risk for surgical AVR (logistic Euroscore ≥ 20% and/or surgical assessment).
Methods: The Cribier-Edwards valve is a trileaflet equine pericardial valve mounted 
inside a stainless steel stent. Under general anesthesia, a 22F or 24F sheath was placed 
in the femoral artery following aortic valvuloplasty. The PHV was advanced using a tip-
deflecting catheter, positioned, and deployed during rapid pacing.
Results: 28 patients (64% female, mean age 83 years [range 69-100]) with mean 
aortic valve area 0.5cm2 and mean logistic Euroscore 30.5% were enrolled at Columbia 
University. TAVR was successfully performed in 24 (86%) patients (23mm valve - 10 
and 26mm valve - 14). Two implantation failures resulted in death from type A aortic 
dissections and two failures resulted from inability to insert the PHV sheath due to severe 
vascular disease. In all 24 patients with successful TAVR, mean gradient was significantly 
reduced (< 5mmHg) with post-procedure valve areas >1.7cm2, and >2+ para-valvular 
aortic regurgitation in only 1 patient (4%). Periprocedural mortality was 7% (2/28) and 
MACE (death, MI, major stroke, major vascular complication) was 21% (6/28). Median 
length of stay post procedure was 7 days (2-44). At 30 days, there was no additional 
MACE. There were two procedure related readmissions in the first 30 days (DVT and 
wound infection). After successful TAVR, mean NYHA functional class was reduced from 
3.1 at baseline to 1.5 at one month (p<0.01). Six month clinical and echocardiographic 
outcomes will be presented.
Conclusion: TAVR is feasible and results in lower than predicted periprocedural mortality 
for high-risk surgical AVR. While periprocedural MACE rates remain high, with reduction of 
device profile and a covered delivery system, vascular complications may be reduced.
2:30 p.m.
816-5 Early North American Experience with Percutaneous 
Aortic Valve Replacement (CoreValve) in Patients 
Unsuitable for Surgical Aortic Valve Replacement
Colin Berry, Yoan Lamarche, Bertrand Marcheix, Anita Asgar, Andre Denault, Arsene 
Basmadjian, Jean-Claude Laborde, Raymond Cartier, Raoul Bonan, Montreal Heart 
Institute, Montreal, PQ, Canada
Background: Percutaneous aortic valve replacement (PAVR) with the CoreValve Revalving™ 
system is an emerging therapy for non-surgical patients with severe aortic stenosis (AS).
Methods: Patients with severe (area <0.6 cm2/m2) AS who had been refused surgery 
due to comorbidity were enrolled. We performed general anesthesia, surgical arterial 
access and either femoral vein-femoral artery cardiopulmonary bypass (CPB) or use of a 
left atrial-to-femoral artery percutaneous ventricular assist device (PVAD, TandemHeart). 
Percutaneous coronary intervention (PCI) and peripheral transluminal angioplasty (PTA) 
were performed where appropriate. Aortic balloon valvuloplasty was performed first, then 
retrograde CoreValve PAVR.
Results: Seventeen women and 12 men (age range 64-90 yrs) were referred (March05-
Aug.06) for PAVR. Six women and 7 men (mean (SD) age 82 (10) years) gave informed 
consent. Two of these patients had non-permissive vascular access, thus 5 women and 
6 men underwent PAVR. Their median logistic EuroScore was 36%, the mean AV area 
was 0.56(0.19) cm2, and their median NYHA class was 3. One patient underwent PCI with 
a drug-eluting stent combined with simultaneous PAVR. Two male patients needed left 
iliac artery PTA to permit device advancement. Median (interquartile range) CPB duration 
was 30 (26, 44) min. The post-PAVR aortic bioprosthetic valve area was >1.2cm2 and 
paravalvular regurgitation was ≤grade 2. PVAD was used in the two most recent cases. 
One man had a stroke and died 5 days post-PAVR. One woman with a mitral prosthesis 
had a cerebral bleed and died 20 days post-PAVR. Three patients required permanent 
pacemaker implantation. Follow-up of survivors (range 1 to 8 months; Aug.25, 2006) 
confirmed hemodynamic and functional improvements in all cases. The mean AV area at 
1 month was 1.3(0.4)cm2 (P<0.001 vs pre-PAVR). The mean (SD) LVEF increased from 
49(17)% pre-PAVR to 56(11)% 1 month post-PAVR (P<0.001). Five patients who were 
referred for PAVR died during screening.
Conclusions: PAVR is feasible and can be performed with a PVAD. PAVR may be 
combined with PCI and may need PTA. Future lower profile devices (eg 18 Fr) should 
permit inclusion of a broader range of high-risk patients for PAVR.
2:45 p.m.
816-6 Primary Percutaneous Coronary Intervention Lowers 
Incidence of Ischemic Mitral Regurgitation
Sarah Chua, Judy Hung, Sheng-Ying Chung, Morgan Fu, Chung Ren Wu, Han Kon Yip, 
Chi Ling Hang, Mien Chen Chen, Chang Gung Memorial Hospital,Kaohsiung Medical 
Center,Chang Gung University,College of Medicine, Kaohsiung Hsien, Taiwan,ROC, 
Massachusetts General Hospital, Boston, MA
Background:Mitral regurgitation (IMR) resulting from acute myocardial infarction (AMI) 
leads to significant morbidity and mortality. It is unknown if primary percutaneous coronary 
intervention (PCI) for AMI leads to a decrease in the incidence of IMR. We aimed to examine 
if pts who underwent primary PCI for first AMI resulted in a decrease in IMR incidence.
Methods:We examined the medical database from 2000-2004 for first AMI pts. They were 
grouped into whether they underwent revascularization (+PCI) or no revascularization (-
PCI). Clinical characteristics and hemodynamic data were collected. Their 2D Echo were 
reviewed, and MR degree assessed by jet area (graded 0-4; 0=none to 4=severe). They 
were substratified into MR=0-2 and MR=3-4.
Results:1040 pts were examined (809+PCI, 231 -PCI). There was no difference in age 
and gender between the groups or distribution of MI type (anterior vs. inferior). The 
follow up period was 2160 days. In the +PCI group, there was a significant decrease in 
the incidence of IMR (10.4 % vs. 28.1% +PCI vs. -PCI; p<0.001). There was a greater 
incidence of IMR with inferior vs. anterior MI (12.8% vs. 8.6%; p<0.001). In inferior MI, 
PCI resulted in a greater decrease in IMR incidence than in anterior MI compared to 
no revascularization (19.9% vs. 17.6%; p<0.05). The adjusted hazard ratio of +PCI for 
incidence of MR was 0.337 (p<0.001; 95% CI: 0.229-0.495).
Conclusions:Primary PCI for AMI pts decreases the incidence of IMR. PCI for inferior MI 
had a greater decrease in IMR than in anterior MI.
Table 1. Overall Incidence of Ischemic MR among those with +PCI vs. -PCI
Total (N=1040) +PCI (n= 809) -PCI (n= 231)
Difference 
between 
+PCI vs. 
-PCI
MR grade 0-2 (n=725)
3-4
(n=84)
0-2
(n=166)
3-4
(n=65)
Age 61.9±12 66.7±11 65.7±13 70.5±11
No. and (%within PCI) 725 84 *(10.4%) 166 65 * (28.1%) § 17.7%
*p<0.001
Anterior MI No. and (%) 499 47 * (8.6%) 131 46 (26%) φ17.6%
Inferior MI No. and (% ) 224 33 * (12.8%) 37 18 (32.7%) φ19.9%φp<0.05
+PCI denotes underwent revascularization; -PCI denotes no revascularization
MR denotes mitral regurgitation, * p value <0.001 calculated by chi square
§ Hazard ratio :0.337; (p<0.001; 95% confidence interval: 0.229-0.495).
φp<0.05 (by Fisher’s exact-test ) of reduction in % of IMR among inferior MI +PCI vs. 
anterior MI +PCI
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816-7 Significant Reduction in Mitral Regurgitation Six 
Months Following Percutaneous Mitral Valve Repair 
with the MitraClip™
Elyse Foster, Anuradha Tunuguntla, Patrick L. Whitlow, Peter C. Block, Howard C. 
Herrmann, Paul Kramer, Richard Smalling, Steven Bailey, Michael J. Rinaldi, William A. 
Gray, Ted Feldman, University of California, San Francisco, San Francisco, CA
Background: A percutaneous method (MitraClip Evalve, Inc. Menlo Park, CA) for correction 
of mitral regurgitation (MR) using a clip to achieve leaflet apposition was recently described. 
6 month echocardiographic (echo) results were analyzed by a core laboratory.
Methods: 55 enrolled patients had moderately severe or severe baseline MR 
(degenerative-47, functional-8). Echos performed at multiple points included baseline 
and 6 months post-clip. Four variables were measured: regurgitant volume (RV), 
regurgitant fraction (RF), pulmonary vein flow pattern (PVF) and color flow Doppler grade 
(CFD). An overall composite MR grade was assigned. Standard American Society of 
Echocardiography criteria were used for each variable.
Results: The clip was implanted in 49 out of 55 patients. 8 subsequently required surgery 
for MR within 6 months, there was 1 unrelated death and 1 echo was unavailable. In 
the 39 patients with a clip evaluated at 6 months, all measures of MR severity were 
significantly decreased (table). Of the 39 pts, 28 (67%) had moderate MR ≤2+ at 6 months 
(degenerative-24, functional-4). In this group, the improvements were more marked in all 
quantitative variables (table).
Conclusions: Percutaneous mitral valve repair resulted in sustained reduction in MR severity 
to moderate or less in the majority of patients, as documented by systematic quantitative echo. 
39 patients with clip at 6 months 28 stable patients (MR ≤ 2+ at 6-months) 
N Baseline 6-Month Change P* N Baseline 6-Month Mean p*
Overall
MR grade 37 3.5 (0.6) 1.8 (1.0) -1.7 (1.0) <0.0001 26 3.3 (0.6) 1.3 (0.4) -2.0 (0.7) <0.0001
RV (ml) 31 50.3 (21.5) 27.5 (18.6) -22.8 (17.5) <0.0001 24 48.2 (20.3) 22.0 (13.0) -26.2 (16.9) <0.0001
RF (%) 31 44.6 (13.6) 28.9 (15.3) -15.7 (16.5) <0.0001 24 45.1 (12.3) 25.5 (12.9) -19.6 (14.2) <0.0001
CFD
(Grade) 38 3.4 (0.7) 1.8 (0.9) -1.6 (1.0) <0.0001 27 3.1 (0.7) 1.4 (0.5) -1.8 (0.9) <0.0001
PVF (cm/s) 21 2.8 (1.2) 1.8 (1.1) -1.0 (1.2) 0.0053 13 2.4 (1.2) 1.1 (0.3) -1.3 (1.2) <0.0018
All values are mean (SD) P* T-test P value
3:15 p.m.
816-8 17 Years Clinical And Echocardiographic Follow-Up 
Results Of Mitral Balloon Valvuloplasty In 520 Patients 
And Predictors Of Long-Term Outcome
Mohamed Eid Fawzy, Jehad Al Buraiki, Maie Al Shahid, Suleiman Kharabsheh, Hassan 
ElWidaa, Abdelmoneim ElDali, Aly Al Sanei, Charles C. Canver, King Faisal Specialist 
Hospital and Research Centre, Riyadh, Saudi Arabia
Background and Aims: Long-term echocardiographic follow-up studies of mitral balloon 
valvuloplasty (MBV) are scarce. The aim of this study was to assess the long term 
results (up to 17 years) of mitral balloon valvuloplasty (MBV) and to identify predictors of 
restenosis and event-free survival.
Methods and Results: We report the immediate and long term clinical and echocardiographic 
results in 520 patients, mean age 31 ± 11 years, who underwent successful MBV for severe 
Mitral Stenosis (MS) and were followed up for 1 - 17 (mean 7.3 ± 4.35) years. After MBV, 
mitral valve area (MVA) increased from 0.84 ± 0.2 to 1.82 ± 0.53 cm2 (P < 0.0001) as 
measured by catheter and from 0.92 ± 0.17 to 1.95 ± 0.29 cm2 (P < 0.0001) as measured by 
2D echo. Restenosis occurred in 133 patients (25.6%) and it was less frequent in patients 
with low mitral echo score (MES ≤ 8) (16.7%). Actuarial freedom from restenosis at 10, 15, 
16 years were 73 ± 2%, 43 ± 4% , 23 ± 6% respectively, and was significantly higher in 
patients with low echo score 84 ± 2%, 52 ± 6%, 36 ± 9% respectively (P < 0.001). Event-
free survival (death, redo MBV, Mitral Valve Replacement, NYHA Functional Class III or IV) 
at 10, 15, 16 years were 82 ± 2%, 45 ± 5%, 31 ± 6% respectively, and was significantly 
higher for patients with echo score ≤ 8, 90 ± 2%, 60 ± 5%, 51 ± 8% respectively (P < 0.001). 
Cox regression analysis identified MES (P < 0.0001), Post procedure MVA (P = 0.044) as 
predictors of restenosis and MES (P < 0.0001) and age (P<0.0001) and post procedure 
MVA (P = 0.016) as predictors of event free survival.
Conclusions: MBV provides excellent long-term results for selected patients with MS. 
The long-term outcome after this procedure can be predicted from baseline clinical and 
mitral valve morphology as assessed by echo score.
ACC.ORAL CONTRIBUTIONS
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839-3 Metabolic Profile of the Elderly with a Calcific Aortic 
Stenosis and its Relation with the Valvular Calcium Content
Dania Mohty, Jr., Philippe Pibarot, Jr., Claude Côté, Amélie Cartier, Benoit Arsenault, 
Andrée Pépin, Jean-Pierre Després, Sr., Patrick Mathieu, Jr., Laval Hospital, Québec, 
PQ, Canada
Background: Aortic stenosis (AS) is considered as an atherosclerotic-related process. 
However, there are uncertainties whether AS in the elderly is associated with the same 
pathophysiological process as in the younger patients. We have hypothesized that the 
metabolic profile of the elderly with a severe AS would be different from the younger ones 
and that it would have a relationship with the calcifying process.
Methods: In 77 patients operated for a severe AS, a complete lipid blood profile including the 
size of LDL particles, along with the plasma levels of adipokines (resistin, leptin, adiponectin) 
were determined. In addition, anthropometric measurements including the waist circumference 
was obtained for every patient. Calcium content of the aortic valve was determined and 
valvular inflammation was quantified using immunohistochemistry to document the level of 
TNF-α and the density of macrophages (CD68+), and T cells (CD3+).
Results: Older patients (> 70 years; n=44) had a significantly lower body mass index 
(BMI) (p=0.01), waist circumference (p=0.04), LDL-cholesterol level (p=0.002), triglyceride 
(p=0.002), cholesterol/HDL ratio (p<0.0001) and lower percentage of small (< 255 Å) LDL 
particles (p=0.03). However, they had increased plasma levels of leptin (p=0.03), resistin 
(p=0.008) and adiponectin (p=0.02). When compared to younger patients, AS valves of 
the elderly had a similar amount of calcium content, inflammatory infiltrates and TNF-α 
expression. Among the different metabolic markers, only resistin was associated with the 
valvular calcium content (p=0.04). Resistin blood level was not correlated to glycemia nor 
the body mass index or the waist circumference. It was, however, correlated with leptin 
blood level (r=0.29; p=0.02).
Conclusion: The metabolic profile of elderly patients was less atherogenic than that of 
younger patients. On the other hand, they had higher plasma level of resistin, which was 
the only metabolic marker associated with the amount of valvular calcification. These results 
suggest that, beyond atherosclerotic pathways, aging-related process affecting adipokines 
pathway may also be involved in the development of calcific AS in elderly patients.
9:15 a.m.
839-4 Calcific Aortic Stenosis Is Independently Associated 
With Increased Parathormone Serum Level in Coronary 
Artery Disease Patients
Katerina Linhartova, Roman Cerbak, Gabriela Sterbakova, Jaroslav Racek, 
Vladislav Trefil, Josef Veselka, Charles University School of Medicine Hospitals 
Motol, Prague, Pilsen, Czech Republic, Center for Transplantation and 
Cardiovascular Surgery, Brno, Czech Republic
Background: In calcific aortic valve disease, the early sclerotic valve lesion is similar 
to the atherosclerotic arterial plaque, but at the later stage calcification prevails. 
Parathormone (PTH) is the principal regulator of the calcium pool. Our aim was to assess 
the association of PTH and calcium metabolism with aortic stenosis (AS) in patients with 
significant coronary artery disease.
Methods: We prospectively enrolled consecutive patients with angiographically significant 
coronary artery disease associated with AS (mean transvalvular aortic gradient ≥30 mm 
Hg) or nonobstructive aortic sclerosis (mean gradient ≤10 mmHg). We compared the 
fasting serum PTH level and calcium turnover parameters between the two groups, and 
identified independent risk factors of AS in the multivariate logistic regression model.
Results: We included 122 pts. with AS (85 males) and 101 pts. with aortic sclerosis (76 
males). The AS patients were older (71±7 vs 66±7 years; p<0.001), had higher serum PTH 
level (57±26 vs 40±18 pg/ml; p<0.001), higher 24-hour urinary phosphorus (P) excretion 
(21±12 vs 17±10 mmol/24 hours; p=0.01), and lower creatinine clearance (1.14±0.4 vs 
1.25±0.3 ml/sec; p=0.04) than those with aortic sclerosis. Between both groups, there 
were no statistically significant differences in the serum P and ionized calcium level, 24-
hour urinary calcium excretion, and in the occurrence of the major cardiovascular risk 
factors: hypertension, smoking, diabetes, dyslipidemia, LDL and HDL cholesterol levels, 
body mass index, and high sensitivity C-reactive protein. The PTH level (OR 1.04, 95%CI 
1.02-1.05; P<0.001) and age (OR 1.09, 95%CI 1.03-1.14; P<0.001) were independently 
associated with AS.
Conclusion: Elevated serum PTH was independently associated with calcific AS in 
coronary artery disease patients. Increased urinary P excretion also suggests, that higher 
calcium turnover may be associated with valve calcification in these patients.
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839-5 Association Between Plasma LDL Particle Size, Valvular 
Infiltration by Oxidized LDL and Inflammation in 
Patients with Severe Aortic Stenosis
Dania Mohty, Jr., Philippe Pibarot, Jr., Claude Côté, Benoit Arsenault, Amélie Cartier, 
Andrée Pépin, Jean-Pierre Després, Patrick Mathieu, Jr., Laval Hospital, Sainte-Foy, 
PQ, Canada
Background: Oxidized LDL (ox-LDL) is a powerful inflammatory factor in the atherosclerotic 
plaques. Several studies have suggested that calcified aortic stenosis (AS) is related to an 
atherosclerotic-like process. The objective of this study was thus to examine the association 
between: 1) the plasma metabolic profile and the presence of ox-LDL within the aortic valve 
and 2) the ox-LDL accumulation and the degree of valvular inflammation.
Methods: Immunohistochemistry analysis was used to detect and quantify (scale 0-3) 
ox-LDL and TNFα accumulation in 75 valves explanted from patients with AS. The density 
of leukocytes (CD45+), macrophages (CD68+), and T cells (CD3+) was also determined. 
A standard plasma lipid profile was obtained in each patient and the percentage of small 
size LDL particles subfraction (< 255 Å) was measured.
Results: There was a significant association between the percentage of small size 
LDL particles in the plasma and ox-LDL score within the valve (p=0.03), whereas total 
cholesterol and LDL levels were not associated. The patients with a valvular ox-LDL score 
= 3 had a higher percentage of small size LDL particles (51±6%) compared to those with 
a score = 0 (24±4%). In turn, valves with higher ox-LDL content were associated with 
increased numbers of leucocytes (p=0.03), macrophages (p=0.008), and T cells (p=0.03) 
as well as with increased expression of TNFα (p=0.002). Finally, patients with an ox-
LDL score = 3 also had a much more rapid preoperative hemodynamic progression of 
their stenosis as measured with the annualized progression rate of peak transvalvular 
pressure gradient (p=0.04). 
Conclusion: This study suggests that valvular ox-LDL may have an important contributory 
role in the inflammatory process leading to active calcification of the aortic valve. 
Furthermore, small size LDL subfraction, but not total cholesterol nor LDL-cholesterol 
level, was associated with increased valvular ox-LDL content in severely stenotic valves. 
These results therefore suggest that, beyond lipid-lowering therapy, a therapy aimed at 
lowering the proportion of small size LDL particles might represent a new and efficient 
therapeutic avenue to alter the progression of moderate-severe AS.
9:45 a.m.
839-6 Low Fetuin-A Concentrations Predict the Progression 
of Aortic Valve Calcification
Ralf Koos, Vincent Brandenburg, Andreas Horst Mahnken, Georg Mühlenbruch, Markus 
Ketteler, Malte Kelm, Harald Peter Kühl, University hospital RWTH Aachen, Aachen, Germany
Background: Human fetuin-A (alpha2-Heremans Schmid glycoprotein) has been 
identified as the most potent circulating inhibitor of vascular and soft-tissue calcification. 
The aim of the present study was to investigate the relationship between the serum fetuin-
A level and the progression of aortic valve calcification (AVC) assessed by retrospectively 
ECG-gated Multislice Spiral Computed Tomography (MSCT) in patients with calcific aortic 
valve disease.
Methods: A prospective study in 35 non-dialyzed patients (mean age 70 ± 8 years, 27 
men) with echocardiographically proven aortic valve disease was performed. In all patients 
serum fetuin-A levels were measured by nephelometry (BNII, Dade Behring Holding, 
Liederbach, Germany) using a polyclonal rabbit anti-human antibody against fetuin-A. 
For quantification of AVC all patients underwent 16-slice MSCT (Sensation 16, Siemens, 
Forchheim, Germany with scan parameters as follows: 420ms tube rotation time, 12x 
0.75mm collimation, 133mAs tube current, tube voltage 120KV). After a mean follow-up 
of 12.8 ± 1.8 months (range 8-18 months) a second non-enhanced MSCT examination 
for quantification of AVC was performed. Images were reconstructed at 60% of the RR 
interval with an effective slice thickness of 3mm and a reconstruction increment of 2mm. 
AVC was assessed using Agatston AVC score and volumetric AVC score. The patients 
were stratified according to the median of fetuin-A (cut-off 0.714g/L) into 2 groups.
Results: Patients with low fetuin-A levels (n=19) showed a significantly higher progression 
of aortic valve calcification (increase of volumetric AVC score: 33.2 ± 23.7%; increase of 
Agatston AVC score 36.9 ± 28.2%) compared to patients with high fetuin-A levels (n=16; 
increase of volumetric AVC score 12.6 ± 19.2%, p=0.008; increase of Agatston AVC score 
13.6 ± 23.5%, p=0.01).
Conclusion: Low fetuin-A serum levels indicating systemic calcification inhibitor 
deficiency were associated with increased progression of aortic valve calcification.
10:00 a.m.
839-7 Relationship Between Circulating Uncarboxylated 
Matrix-Gla Protein Concentrations and Aortic Valve 
Calcification
Ralf Koos, Harald Peter Kühl, Cees Vermeer, Vincent Brandenburg, Andreas Horst 
Mahnken, Malte Kelm, Leon Schurgers, University hospital RWTH Aachen, Aachen, 
Germany, Cardiovascular research institute CARIM and VitaK , Maastricht University, 
Maastricht, The Netherlands
Background: Matrix Gla protein (MGP) is a vitamin K-dependent protein. Recently, the 
uncarboxylated (inactive) form of MGP was associated with vascular tissue calcification. 
The aim of the present study was to investigate the relationship between the circulating 
uncarboxylated (uc) MGP levels and the presence of aortic valve calcification (AVC) 
assessed by retrospectively ECG-gated Multislice Spiral Computed Tomography (MSCT) 
in patients with calcific aortic valve disease.
Methods: A prospective study of 176 non-dialyzed patients (mean age 71 ± 9 years, 
126 men) with echocardiographically proven aortic valve disease was performed. In all 
patients circulating ucMGP levels (in nM compared to synthetic ucMGP) were measured 
by a competitive ELISA-based assay. For quantification of AVC all patients of the study 
cohort underwent 16-slice MSCT (Sensation 16, Siemens, Forchheim, Germany). A 
reference population with 76 healthy control patients (mean age 39 ± 14 years, 37 male) 
defined from the patient chart were recruited. 
Results: Patients with aortic valve calcification (study cohort) showed significantly lower 
ucMGP levels as compared to healthy control patients (mean ± SD; 343 ± 124nM vs. 
493 ± 111 nM, p<0.001). No correlation between ucMGP levels and Agatston AVC score 
assessed by MSCT was observed (r= 0.01, p=0.93) in the study cohort. Patients with 
long-term oral anticoagulation therapy (>48 months, n=17) showed decreased ucMGP 
levels (274 ± 87 nM) and a trend towards increased Agatston AVC score (2306 ± 1940) 
compared to patients without anticoagulation (n=137; ucMGP 342 ± 123 nM, p=0.008; 
Agatston AVC score 702 ± 752, p=0.12).
Conclusions: Decreased ucMGP levels indicating calcification inhibitor deficiency were 
associated with the presence of aortic valve calcification compared to a healthy reference 
population. In addition, oral anticoagulation may be linked to decreased ucMGP levels. 
Longitudinal data are needed to evaluate if MGP may become a suitable biomarker for 
the progression of aortic valve calcification.
10:15 a.m.
839-8 An Atherosclerotic Process is Involved in The 
Structural Valve Deterioration of Bioprostheses
Rahul Shetty, Jr., Philippe Pibarot, Jr., Claude Côté, Amélie Cartier, Jean-Pierre 
Després, Sr., Patrick Mathieu, Jr., Laval Hospital, Québec, PQ, Canada
Background: Until now the structural valve deterioration of bioprosthetic (BP) valves 
has been considered as a purely passive degenerative process and the strategies to 
prevent SVD have been therefore focused on the pre-treatment with anti-calcifying 
agents. Although these agents are very efficient to prevent BP calcification in animal 
models, the incidence of SVD still remains a frequent problem that limits the longevity of 
BPs. We hypothesized that atherosclerotic and inflammatory mechanisms are involved 
in the SVD of BPs.
Methods: Fifteen Freestyle stentless BP valves (valve model pretreated with amino-oleic 
acid) were explanted for SVD at a mean time of 4.9±2.8 years after BP implantation and 
were analysed by immunohistochemistry and electronic transmission microscopy (EM).
The mean age of the patients was 71 years and there were 9 females and 6 males.
Results: One out of the15 BPs had macroscopic calcification whereas the other valves 
had minimal or no visible calcification. Tears at the commissure leading to regurgitation 
was present in 14 BPs. Analyses with light transmission microscopy demonstrated foci of 
calcification (Von Kossa staining) in only 3 BPs, whereas fragmentation of collagen was 
demonstrated in 10 valves. Immunohistochemistry demonstrated the presence of oxidized-
LDL (ox-LDL) in 10 BPs which was localized in the fibrosal layer. Densely infiltrated areas 
with ox-LDL were infiltrated by macrophages (CD68+) co-expressing metalloproteinase-
9 (MMP-9). Zymogram demonstrated the active form of MMP-9 within BPs. EM studies 
revealed the presence of lipid laden-cells featuring foam cells within leaflet tissue.
Conclusions: These results support the concept that active mechanisms akin to 
atherosclerosis may have an important contributory role in the SVD of BPs. These findings 
open new therapeutic avenues for the prevention of SVD. In particular, the modification 
of atherosclerotic risk factors with the use of behavioral or pharmacological approaches 
may be useful to avoid SVD or reduce its progression.
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1027-15 Comparison of Stentless Valve Implantation Techniques in 
Large Cohort of Patients from the Freestyle Valve Registry.
Anthony J. Rongione, Alan M. Speir, Scott D. Barnett, Paul S. Massimiano, Nelson A. 
Burton, Lucas R. Collazo, Edward A. Lefrak, Niv Ad, Inova Heart and Vascular Institute, 
Falls Church
Background: There has been an increasing trend toward using stentless aortic 
bioprosthesis to achieve better hemodynamics across the aortic valve and lower the 
incidence of patient prosthetic mismatch. The purpose of this study is to compare two 
different implantation techniques (full root Vs subcoronary) from a large cohort of patients 
(939 patients) abstracted from the University of Michigan Freestyle Valve Registry. 
Methods: Patients were categorized into two groups: subcoronary implantation (SC; 
n=482) and full root implantation technique (FR; n=457). Patient prosthetic mismatch 
(PPM) was calculated as EOAI ≤ 0.85. Unconditional logistic regression was used to 
generate Odds Ratios (OR) and 95% Confidence Intervals (CI) for rates of periperative 
morbidity and mortality based on STS guidelines and after adjustment for preoperative 
clinical and demographic characteristics between groups.
Results: Patients were primarily male (66%), white (86%) and 61.5 years of age. 
Overall mortality was 2.1% for SC group and 2.6% for the FR group (p>0.05). Rates 
of perioperative complications were comparable between groups. After adjustment for 
potential preoperative clinical and demographic variables, the SC patients were less 
likely to experience reoperation for bleeding (OR: 0.25, 95% CI: 0.07-0.91) and received 
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fewer blood products (OR: 0.14, 95% CI: 0.06-0.32). The patients in the SC group were 
more likely to experience PPM compared to full root patients (15.6% vs. 9.2, p<0.01. No 
patients in either group experienced severe PPM. (EOAI ≤ 0.65).
Conclusions: Patients following aortic stentless valve implantation have a very low overall 
incidence of PPM. Comparisons of the two implantation techniques suggest that the full root 
technique is safe and may have a lower incidence of patient prosthetic mismatch.
9:00 a.m.
1027-16 Effect Of Bisoprolol And Carvedilol In Atrial Fibrillation 
(af) In Heart Failure Patients After Cardiac Surgery
Giuseppe Marazzi, Maurizio Volterrani, Giuseppe Caminiti, Antonella Aloisio, Viviana 
Maestrini, Marco Miceli, Giuseppe Rosano, Division Of Cardiology, San Raffaele Irccs 
Rome, Rome, Italy
Background: AF is a common event after cardiac surgery with an incidence of 10 to53%. 
This arrhythmia increases complications in the post-surgical period. Furthermore, in heart 
failure patients, AF is one of the most destabilizing complications during post-surgery 
period. Recent evidences suggested that Amiodarone may be effective in the prophylaxis 
of AF, in patients submitted to cardiac surgery. However the percentage of post-surgical 
AF still remains high (25- 35 %). Previous study showed that a beta blockers (BB) reduce 
the incidence of arrhythmic complications in post-surgical heart failure patients. This 
therapy seems to be promising, but degree of effectiveness among different BB still 
remains unclear.
Aim: This study aimed to evaluate the difference of effectiveness between two BB 
(Bisoprolol and Carvedilol) in preventing AF in heart failure patients, after cardiac surgery.
Methods: We randomised 300 patients (176 males and 124 females, aged 68 ± 4 years) 
with heart failure (EF < 40%), NYHA class I/II = 238; NYHA class III = 62, admitted 
consecutively in our Department, after cardiac surgery (max 5 days) . All pts received 
background Amiodaroe therapy and were allocated into 2 groups : Group A (150 pts) was 
treated with Bisoprolol and the Group B (150 pts) with the Carvedilol.
BB therapy was optimized to the maximum dosage tolerated for each patients, 
following guidelines.
At the enrolment, before and after rehabilitation program and one month after 
discharge, all patients underwent clinical evaluation, ECG ,echocardiogram, and 
functional capacity determination.
Results At the enrolment, discharge and follow up, no statistical difference in clinical 
or instrumental parameters and the functional capacity, was detected between the two 
groups: Group A showed 43 (29%) AF events; group B 63 (42%) AF events. However, 
Bisoprolol was more effective in preventing the occurrence of a second episode of AF in 
those pts who had already suffered one (16 pts Vs 25 pts p< 0.05).
Conclusions: According to the results, both Bisoprolol and Carvedilol seem to be 
effective in preventing AF in post-surgical heart failure patients, and Bisoprolol being 
more appropriated.
9:00 a.m.
1027-17 Left Atrium Volume Index Related with Pathological 
Findings as a Predictor of the Success of Sinus 
Conversion with the Maze Procedure in Patients with 
Chronic and Valvular Atrial Fibrillation
Tetsuro Kataoka, Shuichi Hamasaki, Sanemasa Ishida, Masakazu Ogawa, Keishi 
Saihara, Hideki Okui, Noya Oketani, Hitoshi Ichiki, Yuichi Ninomiya, So Kuwahata, 
Shoji Fujita, Toshinori Yuasa, Katsumi Inoue, Chuwa Tei, Graduate School of Medicine, 
Kagoshima University, Kagoshima, Japan
Background: Previous studies showed that surgical maze procedure can restore sinus 
rhythm in patients with chronic atrial fibrillation (AF). Several studies have documented 
that the success of maze procedure was highly related with age, cardiac thoracic rate on 
chest X ray, duration of chronic AF, amplitude of f-wave in V1 lead, and left atrium diameter. 
However, no previous studies discussed the association between left atrium volume index 
and the success of sinus conversion in patients with chronic and valvular AF.
Methods: A total of 78 chronic AF patients undergoing valvular operations were enrolled 
in this study. The success of maze procedure was analyzed with relation to age, cardiac 
thoracic rate on chest X ray, duration of chronic atrial fibrillation, amplitude of f-wave in 
V1 lead, left atrium diameter and left atrium volume index. Furthermore, we evaluated the 
pathological characteristics of tissue derived from left atrial appendage and analyzed with 
relation to the succsess of maze procedure.
Results: After maze procedure, 40 (51%) patients remained in AF (Failure group) and 
38 (49%) patients returned to sinus rhythm (Success group). With regard to amplitude of 
f-wave in V1 lead and left atrium diameter, there was no significant difference between 
the two groups (0.21±0.13 mV vs. 0.26±0.31 mV, p=NS; 55±8 mm vs. 53±9 mm, p=NS), 
whereas age, cardiac thoracic rate, and duration of chronic AF were significantly greater 
in Failure group than in Success group (66±8 y.o. vs. 61±11 y.o. , p<0.05; 60±6% vs. 
56±5%, p<0.001, 102±95 mo. vs. 47±83 mo., p<0.001). Additionally, left atrium volume 
index was also significantly greater in Failure group than in Success group (128±82 
mm3/m2 vs. 80±22 mm3/m2, p<0.01). A pathological examination revealed that left 
atrium appendage tissues in Failure Group showed more remarkable degeneration of 
myocardial cell, interstitial fibrosis and replacement of adipose when compared with 
those in Success Group.
Conclusions: These results indicate that increased left atrium volume index, which may 
be related with pathological degenerative change, appears to predict the failure of sinus 
conversion with the maze procedure in patients with chronic and valvular AF.
9:00 a.m.
1027-18 Safe Use of Clopidogrel and Aspirin Anti-Platelet Therapy 
After Off Pump Coronary Artery Bypass Graft Surgery
Mital Sheth, Abhijit Dasgupta, Scott Silvestry, Suzanne Adams, Jocelyn A. Andrel, Sofia 
Medvedev, David J. Whellan, Thomas Jefferson University, Philadelphia, PA
Background: The off extra-corporal pump coronary artery bypass (OPCAB) procedure 
is a popular alternative; currently about 20% of cardiac bypass surgeries are performed 
off-pump. One concern is the lack of platelet inhibition as a result of OPCAB. Trials of 
clopidogrel use in OPCAB patients have shown contrasting results. We hypothesized 
that use of clopidogrel plus aspirin (ASA) would be safe and provide clinical benefit to 
patients undergoing OPCAB.
Methods: Using the University Health Consortium data from over 40 institutions, 
we identified patients undergoing OPCAB between 2000 and 2005. We excluded 
those receiving post-op anticoagulation for valve replacement and/or atrial fibrillation. 
Pharmacy billing data was used to identify patients treated with ASA alone or ASA and 
clopidogrel. The following events were tracked using administrative coding: cardiac 
complications, stroke, hemorrhage, gastrointestinal hemorrhage, pulmonary embolism 
(PE), and reopening of surgical site (RSS). Logistic regression was used to determine 
associations between drug regimen and comorbidities and complications, adjusting for 
age, race and sex.
Results: 37430 patients underwent OPCAB. Of these, 28101 were given ASA and 9329 
were given ASA and clopidogrel. The use of ASA and clopidogrel vs. ASA alone differed by 
age (median, 72.8 vs. 69, p=0.01); race (% white, 79.3% vs. 74.8%, p<0.01) and by gender 
(% female, 28.4% vs. 32.4%, p<0.01). After adjusting for age, race and gender, there was 
no statistically significant increase in cardiac complications (OR=1.01); stroke (OR=0.90); 
hemorrhage (OR=1.02) and specifically gastrointestinal hemorrhage (OR=1.22, p=0.07) 
in the patients given ASA and clopidogrel. Patients treated with ASA and clopidogrel also 
experienced fewer PE (OR=0.82, p=0.04) and fewer RSS (OR=0.72, p<0.001).
Conclusions: Patients who have OPCAB procedures can safely be treated with ASA 
plus clopidogrel post-operatively without a significant increase in bleeding, PE, and other 
adverse events and may provide clinical benefit. Further prospective studies are required 
to assess any potential long-term benefit.
9:00 a.m.
1027-19 Does the Use of Amiodarone Impact the Ability of 
Anterior Fat Pad Retention to Prevent Post-Operative 
Atrial Fibrillation?
Krista M. Dale, Craig I. Coleman, Jeffrey Kluger, C. Michael White, Hartford Hospital, 
Hartford, CT, University of Connecticut, Storrs and Farmington, CT
Background: The Atrial Fibrillation Suppressions Trial III (AFIST III) found that anterior 
fat pad (AFP) retention did not decrease the incidence of post-operative atrial fibrillation 
(POAF) but prophylaxis with amiodarone did. In order to examine the inter-relationship 
between amiodarone with AFP retention on POAF, we performed a planned subgroup 
multivariate analysis of AFIST III.
Methods: Coronary artery bypass graft (CABG) patients were randomized to AFP 
maintenance or removal with prophylactic amiodarone utilized via blinded-caregivers’ 
discretion. Patients were categorized into four groups: amiodarone + AFP retention, 
amiodarone alone, AFP retention alone, or control ( no amiodarone + AFP removal). 
Multivariate logistic regression was utilized to calculate adjusted odds ratios (OR) with 
95% confidence intervals for development of POAF.
Results: Among the 178 patients (mean age=66±10, 80% male, 5% previous AF) 
receiving CABG surgery, amiodarone was used prophylactically in 28%. The overall 
POAF occurrence rate was 35.4%. Amiodarone + AFP retention was associated with an 
81% reduction in patient’s odds of developing POAF (p=0.015). Amiodarone prophylaxis 
without AFP retention was associated with a 68% reduction (p=0.040). Other independent 
predictors are shown in the table.
Conclusions: Amiodarone prophylaxis with or without AFP retention is an independent 
negative predictor of POAF. Combining amiodarone with AFP retention may provide a 
synergistic effect in the prevention of POAF. 
Table 1: Stepwise logistic regression model for prediction of POAF
Independent variables Odds ratio (95%CI) p value
Prophylactic Amiodarone and AFP Maintenance 0.19 (0.05-0.72) 0.015
Prophylactic Amiodarone and AFP Removal 0.32 (0.11-0.95) 0.04
Age >70 1.98 (0.96-4.07) 0.063
History of AF 8.46 (1.37-52.5) 0.022
Mitral Regurgitation 2.69 (1.05-6.90) 0.04
High-dose NSAIDs 0.46 (0.19-1.12) 0.086
Beta blocker intolerance 3.72 (1.27-10.93) 0.017
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1027-20 Influence of Mitral Inlet Geometry on the Flow Convergence 
Beyond the Anatomic Orifice in Patients with Mitral 
Stenosis: Importance of Flattened Leaflet Shape
Kenichi Nakashiki, Yutaka Otsuji, Takeshi Uemura, Toshinori Yuasa, Eiji Kuwahara, Bo 
Yu, Kayoko Kubota, Naoko Mizukami, Akira Kisanuki, Chuwa Tei, Postgraduate School 
of Medicine, Kagoshima University, Kagoshima, Japan, University of Occupational and 
Environmental Health, Kitakyusyu, Japan
Background: The inlet geometry of the stenosed mitral valve (MV), such as flattened 
leaflet or left atrial (LA) dilatation, has been demonstrated in vitro to exaggerate flow 
convergence beyond the anatomic MV orifice and reduce vena contracta. However, this 
influence has not been fully investigated in patients with mitral stenosis (MS). This study 
tested the hypothesis that flattened mitral leaflet and/or LA dilatation, creating greater MV 
inflow convergence, can correspondingly create a smaller vena contracta (effective MVA) 
beyond the anatomic orifice in patients with MS (figure).
Methods: In 49 patients with MS, the anatomic and effective MVAs were measured by 
2-D echo and the continuity equation with Doppler echo, respectively. In addition to LA 
dimension, mitral annulus antero-posterior dimension (L) and the distance (D) from MV 
orifice to the annulus (Figure) were measured to calculate leaflet flattening index (D/L).
Results: 1) Both increased LA dimension and reduced D/L were significantly correlated 
with reduced effective / anatomic MVA ratio (r= - 0.41 and r= 0.48, p < 0.01), so that 
LA dilatation and flatter leaflets were associated with greater flow convergence beyond 
the anatomic orifice. 2) In addition to the decreased anatomic MVA, smaller D/L was an 
independent determinant of the effective MVA.
Conclusion: Impaired mitral inlet geometry with flattened leaflet or LA dilatation augments 
flow convergence beyond the anatomic orifice and is an incremental and significant factor 
that worsens MS. 
9:00 a.m.
1027-21 Quantitative Assessment of Mechanical Valve using MDCT
Dong-Hyeon Lee, Ho-Joong Youn, Sung-Bo Shim, Sun-Hee Lee, Seung-En Jung, 
Yong-Won Choi, Yun-Seok Choi, Chul-Soo Park, Yong-Seog Oh, Wook-Sung Chung, 
Jae-Hyung Kim, Kyu-Bo Choi, Division of Cardiology, College of Medicine,The Catholic 
University of Korea, Seoul, Korea, Seoul, South Korea
Background:Evaluating mechanical valve function by TTE has limitations due to 
excessive metallic artifact.The aim of this study was to elucidate the assessment of 
mechanical valve function using 64 slice-multidetector computed tomography(MDCT).
Methods: In 20patients(mean age=50±12,M:F=14:16),30St.Jude mechanical 
valves(Aortic valve:Mitral valve=15:15) were evaluated using MDCT.The valve orifice 
area(OA), the valve length and the opening and closing angle were measured.The OA 
and length of mechanical valve were compared with the manufacturer’s values.
Results:The OA based on manufacturer’s value and on MDCT were 3.4±0.2cm2 and 
3.4±0.3cm2 in mitral portion and 2.1±0.3cm2 and 2.1±0.4cm2 in aortic portion, respectively.
Correlation coefficients between the OA based on manufacturer’s value and on MDCT 
were 0.75 in mitral portion and 0.84 in aortic portion,repectively(all p<0.01).The length 
based on manufacturer’s value and on MDCT were 29.3±1.9mm and 29.6±1.6mm in 
mitral portin and 21.5±2.1mm and 20.7±2.3mm in aortic portion, respectively.Correlation 
coefficients between the length based on manufacturer’s value and on MDCT were 1.15 
in mitral portion and 0.79 in aortic portion,repectively(all p<0.01).The each opening and 
closing angle on MDCT were 10.9±0.6° and 131.1±3.2° in mitral portion and 11.1±0.9° 
and 120.6±1.7° in aortic portion.
Conclusions:Our results suggest that the MDCT is a powerful and promising tool to 
assess the function and morphology of mechanical valve. 
9:00 a.m.
1027-22 Epidemiology and Clinical Outcomes of Infective 
Endocarditis in Hemodialysis Patients: Favorable Effect 
of Valvular Surgery
Desikan Kamalakannan, Ram Manohara Pai, Julius M. Gardin, Louis D. Saravolatz, St. 
John Hospital and Medical Center, Detroit, MI
Background: Infective endocarditis is one of the most serious complications of 
bacteremia in patients undergoing chronic hemodialysis. The aim of our study was to 
describe the clinical characteristics, outcome and factors predicting mortality of infective 
endocarditis in hemodialysis patients.
Methods: We performed a retrospective analysis of all patients on chronic hemodialysis 
admitted to a 600-bed urban teaching hospital with infective endocarditis over a 15-year 
period. The Modifed Duke Criteria were retrospectively applied and patients fulfilling 
the criteria for definite endocarditis were included in the study. Patient information was 
collected on risk factors, clinical characteristics, treatment and outcome. Survivors and 
non-survivors were compared to identify factors predicting survival.
Results: Sixty-nine patients on hemodialysis with definite endocarditis were identified. 
The most frequently used dialysis access sites were percutaneous tunneled catheters 
(66.7%). The mean duration of dialysis was 37±32 months. The predominant organism 
was Staphylococcus aureus (57.9%), followed by coagulase-negative staphylococci and 
Enterococcus faecalis. The most frequently infected valves were mitral (49.3%), followed 
by aortic (21.7%) and tricuspid (10.1%) valves. The cardiac and neurologic complication 
rates were 40.6% and 37.7% respectively. Fifteen (21.7%) patients underwent valvular 
heart surgery. The in-hospital mortality was 49.3%. Patients who underwent valvular 
surgery survived more than those who did not have surgery (12/15 vs. 23/54, p=0.01, 
odds ratio 5.39, 95% confidence interval 1.3 - 17.6). On logistic regression analysis, valve 
surgery was the only independent factor predicting survival (p=0.023).
Conclusion: The prognosis of infective endocarditis in hemodialysis patients is poor with 
high mortality. Our data suggest that surgical treatment may improve outcome.
9:00 a.m.
1027-23 The Role of Hepatic Resection in Patients with 
Carcinoid Heart Disease
Alain M. Bernheim, Heidi M. Connolly, Joseph Rubin, Jacob E. Møller, Christopher 
Scott, David M. Nagorney, Patricia A. Pellikka, Mayo Clinic, Rochester, MN
Background: Carcinoid heart disease typically occurs when the right heart is exposed to 
vasoactive substances released from hepatic metastases. The effect of hepatic resection on 
progression of heart disease and survival in patients with carcinoid heart disease is unknown. 
Methods: From our database of patients with carcinoid heart disease, we calculated 
survival from first diagnosis of cardiac involvement. Performance of hepatic resection 
during follow-up was entered as a time-dependent covariate in a multivariable analysis. In 
patients with serial echocardiograms more than 1 year apart without intervening cardiac 
surgery, a previously validated cardiac severity score was calculated. A score increase 
exceeding 25% was considered clinically relevant progression.
Results: Of 265 patients with carcinoid heart disease, 31 underwent hepatic resection at 
diagnosis of cardiac involvement or during follow-up. Five year survival was significantly 
higher in these patients (86.5%, 95% confidence interval [CI] 73.5-100) compared to 
patients without hepatic resection (29%, 95% CI 23.3-36.1; p<0.001). Performance 
of hepatic resection during follow-up remained strongly associated with improved 
prognosis after adjusting for age, sex, 5-hydroxyindoleacetic acid level, and New York 
Heart Association class (hazard ratio 0.31, 95% CI 0.14-0.66; p=0.003). Among the 77 
(30%) patients with serial echocardiograms, 10 underwent hepatic resection during the 
observation period, which was independently associated with decreased risk of cardiac 
progression (odds ratio 0.27, 95% CI 0.06 to 0.73; p=0.03).
Conclusions: In patients diagnosed with carcinoid heart disease, performance of hepatic 
resection is independently associated with improved prognosis. This favorable effect may 
be related to decreased progression of cardiac lesions.
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1027-24 Bicuspid Aortic Valve Is Associated With Atrial Septal 
Aneurysm and Mitral Valve Abnormalities
Manjunath Nathan, Shariar Heidary, Padmini Varadarajan, Ramdas G. Pai, USC/Keck 
School of Medicine, Los Angeles, CA
Background: Association of bicuspid aortic (BAV) valve with ascending aortic dilatation 
is attributed to abnormal connective tissue structure. We hypothesized that this may also 
lead to abnormalities in the structure of the mitral apparatus and the atrial septum.
Methods: Eighty consecutive patients with BAV diagnosed by transthoracic 
echocardiography were matched with 60 age and gender matched controls. 
Echocardiograms were analyzed for atrial septal aneurysm (ASA) defined as excessive 
excursion of fossa ovalis >1.0 cm, anteroposterior mitral annulus diameter in end-
diastole, anterior mitral leaflet (AML) length, posterior mitral leaflet (PML) length and any 
mitral valve prolapse.
Results: Thirty-six (45%) of the patients with BAV had atrial septal aneurysm compared 
to 2 (3%) of the controls (p<0.0001). Patients with BAV also had larger mitral annulus 
diameter in diastole (29+5 vs 25+5 mm, p<0.0001) and systole (32+6 vs 29+3 mm, 
p=0.003), longer AML (28+4 vs 26+4 mm, p<0.0001) and PML (19+4 vs 17+4 mm, 
p=0.04). Three (4%) of the BAV patients had mitral valve prolapse compared to none in 
the controls (p=0.11). Both groups were similar in terms of left ventricular dimensions.
Conclusions: Patients with bicuspid aortic valve have a strong association with atrial 
septal aneurysm and larger mitral leaflets and annulus indicating a connective tissue 
abnormality which is more wide spread than the ascending aorta. Clinical implications of 
these novel associations warrant further investigations.
9:00 a.m.
1027-25 Patient-Prosthesis Mismatch Following Mechanical 
Mitral Valve Replacement
Vincent Chan, Buu-Khanh Lam, Thierry Mesana, Marc Ruel, Paul Hendry, University of 
Ottawa Heart Institute, Ottawa, Canada
Background: We conducted a retrospective study to determine the impact of patient-
prosthesis mismatch (PPM) on clinical outcomes (recurrence of heart failure (CHF), 
residual pulmonary hypertension (PHTN) and survival) following bileaflet mitral valve 
replacement (MVR).
Methods: Between 1985 and 2005, 415 patients, mean age 61 ± 11 years, underwent 
MVR (209 SJM, 121 CM, 85 ON-X). Mean follow-up was 4.6 + 3.7 years (median 3.7, 
1917 patient-years). PPM was defined as IEOA < 1.25 cm2/m2. Parametric and non-
parametric analyses were used to determine predictors of outcomes.
Results: The incidence of PPM was 26%. Predictors of recurrent CHF included low 
IEOA (<1.25cm2/m2) (P<.0001), low ejection fraction (P=.03) and coronary artery disease 
(P=.04). Residual PHTN was associated with small mitral size (P=.02), preoperative 
PHTN (P=.02) and older age (P<.0001); low IEOA did not predict PHTN (P=.53). Poor 
late survival was predicted by low IEOA (P=.0002), left ventricular dysfunction (P=.02), 
CAD (P=.03) and presence of atrial fibrillation (P=.002). Survival for patients with PPM 
versus those without PPM at 1, 3, 5 and 10 years was respectively 90% vs 95%, 84% vs 
92%, 79% vs 90% and 68% vs 81% (P=.02).
Conclusions: Mitral valve PPM after bileaflet MVR was associated with recurrence of 
CHF and decreased late survival. It was also indirectly linked to residual PHTN. These 
findings highlight the importance of implanting a sufficiently large prosthesis in adult 
patients undergoing MVR in order to optimize clinical results.
